DRUG NAME: Amoxicillin (Amoxycillin)

INN: Amoxicillin
Indian Pharmacopoeia spelling: Amoxycillin (with “y”) — this older British-style spelling remains on many Indian product labels, prescriptions, and CDSCO documents. Both spellings refer to the identical drug. This monograph uses the INN spelling “Amoxicillin” as primary.

Salt form: Amoxicillin trihydrate is the salt form in all oral formulations marketed in India (capsules, tablets, dispersible tablets, dry syrup). Amoxicillin sodium is the salt form in injectable formulations (where available — limited in India as a single-ingredient injection). All doses in this monograph are expressed as amoxicillin base equivalent unless otherwise stated.

ℹ️ This monograph covers AMOXICILLIN (single ingredient) ONLY. The fixed-dose combination of amoxicillin + clavulanic acid (co-amoxiclav / Augmentin) is a separate drug with a separate monograph — it has different indications, dosing, spectrum, adverse-effect profile, and clinical decision points. Do NOT use this monograph for prescribing amoxicillin-clavulanate.

ℹ️ Relationship to other penicillins:

Property	Amoxicillin (THIS monograph)	Phenoxymethylpenicillin (Penicillin V)	Ampicillin
Spectrum	Aminopenicillin — broader than natural penicillins (covers some gram-negatives: E. coli, H. influenzae, P. mirabilis, Salmonella, Shigella) + retains streptococcal/enterococcal coverage	Natural penicillin — narrow spectrum (gram-positives mainly)	Aminopenicillin — identical spectrum to amoxicillin
Oral bioavailability	✅ ~80–90% — excellent (NOT significantly reduced by food)	~60–73% (reduced by food)	⚠️ ~40–50% (significantly reduced by food)
Acid stability	✅ Acid-stable	✅ Acid-stable	⚠️ Less acid-stable
Food effect	✅ Minimal — can be taken with or without food	⚠️ Significant — take on empty stomach	⚠️ Significant — take on empty stomach
Oral dose frequency	BD or TDS (sufficient due to high bioavailability)	QID (traditional) or BD (accepted for pharyngitis)	QID (required due to poor absorption)
Palatability (suspension)	✅ Good — widely available flavoured suspensions	⚠️ Bitter taste	Variable
Clinical role	Has largely replaced both Pen V and oral ampicillin in Indian practice due to superior bioavailability, food independence, and simpler dosing	Niche: RF prophylaxis (oral alternative), GAS pharyngitis (narrow spectrum advantage)	Largely obsolete as oral drug; IV ampicillin remains useful for specific indications (Listeria, enterococcal infections)

ℹ️ Why amoxicillin dominates Indian outpatient antibiotic practice: Amoxicillin is the most commonly prescribed oral antibiotic in India for community-acquired infections. Its combination of high oral bioavailability (~80–90%), food-independent absorption, good safety profile, affordability (NLEM-listed, NPPA price-controlled), palatability of paediatric suspensions, and broad but not excessively wide spectrum makes it the ideal workhorse antibiotic for Indian primary care. It is the backbone of empirical treatment for upper and lower respiratory tract infections, urinary tract infections, dental infections, H. pylori eradication, and GAS pharyngitis (primary RF prevention) across India.

Therapeutic Class: Antibiotic

Subclass: Aminopenicillin (Beta-Lactam — Penicillinase-Susceptible)

Distinguishes amoxicillin from:

Natural penicillins (benzylpenicillin, phenoxymethylpenicillin) — narrower spectrum, no gram-negative coverage
Penicillinase-resistant penicillins (cloxacillin, flucloxacillin) — anti-staphylococcal, no gram-negative coverage
Aminopenicillin + beta-lactamase inhibitor combinations (amoxicillin-clavulanate) — broader spectrum due to beta-lactamase inhibitor component → covered in separate monograph
Extended-spectrum penicillins (piperacillin) — anti-pseudomonal activity
Ampicillin — identical spectrum but inferior oral bioavailability; largely replaced by amoxicillin for oral use

ℹ️ Penicillinase-susceptible: Amoxicillin (like all aminopenicillins) is hydrolysed by staphylococcal beta-lactamases (penicillinases). It is therefore NOT effective against penicillinase-producing Staphylococcus aureus (>90% of community S. aureus in India are penicillinase-producers). For suspected staphylococcal infections, use cloxacillin (oral or IV) or amoxicillin-clavulanate. Amoxicillin alone is effective against S. aureus ONLY if the isolate is confirmed penicillin-susceptible (rare in Indian clinical isolates).

Schedule (India):

Schedule H

All formulations (capsules, tablets, dispersible tablets, dry syrup/oral suspension, injection) are Schedule H drugs. A valid prescription is required for dispensing.

ℹ️ Despite Schedule H status, amoxicillin is one of the most commonly dispensed-without-prescription antibiotics in Indian retail pharmacies — particularly in smaller towns and rural areas. This contributes significantly to antimicrobial resistance in India and is a regulatory compliance issue, not a legal reclassification.

Route(s):

Oral (capsules — swallowed whole; tablets — swallowed whole or chewed [dispersible tablets]; oral suspension/dry syrup — measured with graduated dosing device)
IV (intravenous — limited availability as single-ingredient injection in India; amoxicillin-clavulanate IV is more widely stocked)
IM (intramuscular — limited use; amoxicillin injection is not widely available as a single-ingredient IM formulation in India)

ℹ️ Oral is the PRIMARY route for amoxicillin in Indian practice. The excellent oral bioavailability (~80–90%) makes it one of the few antibiotics where oral dosing achieves serum levels comparable to parenteral dosing for most non-CNS, non-endovascular infections. Parenteral amoxicillin (single-ingredient) has very limited availability in India — when parenteral aminopenicillin is needed, IV ampicillin is more commonly stocked and used. When parenteral amoxicillin with beta-lactamase inhibitor is needed, IV amoxicillin-clavulanate is widely available.

Biosimilar Status:

Not a biologic — biosimilar classification not applicable. Amoxicillin trihydrate is a small-molecule chemical drug (semi-synthetic aminopenicillin) manufactured by chemical modification of the 6-aminopenicillanic acid (6-APA) core.

Formulations Available in India:

Single-ingredient formulations:

Dosage Form	Strengths Available	Notes
Capsules	250 mg, 500 mg	Standard adult oral formulation. Widely available across India. Swallow whole with water.
Tablets (film-coated)	250 mg, 500 mg, 875 mg	875 mg tablets are used for high-dose regimens (respiratory infections, H. pylori). Film-coated — swallow whole.
Dispersible tablets (DT)	125 mg, 250 mg, 500 mg	WHO-prequalified formulation. Can be dispersed in a small volume of water (10–20 mL) to form a suspension for administration. Suitable for children and patients with dysphagia. Stable in tropical conditions. ℹ️ Dispersible tablets are the WHO-preferred paediatric formulation and are increasingly available in Indian government supply (RNTCP, NHM supply chains) and Jan Aushadhi stores.
Dry syrup / Oral suspension (powder for reconstitution)	125 mg/5 mL, 250 mg/5 mL, 400 mg/5 mL (some brands)	Widely available. Suitable for paediatric dosing. Reconstitute with water as per manufacturer instructions. ✅ Palatability: Good — most Indian brands offer strawberry, orange, banana, or mango flavours. Significantly better-tasting than phenoxymethylpenicillin suspension. Measure with graduated oral syringe or dosing cup — NOT a household teaspoon.
Oral drops (paediatric)	100 mg/mL (some brands)	Concentrated drops for infants. ⚠️ Verify concentration carefully — confusion between 100 mg/mL (drops) and 50 mg/mL or 25 mg/mL (some syrup strengths) can cause dosing errors.
Injection (powder for reconstitution)	250 mg, 500 mg, 1 g vials	⚠️ Very limited availability in India as a single-ingredient injectable. Most hospitals stock IV amoxicillin-clavulanate (co-amoxiclav) or IV ampicillin rather than IV amoxicillin alone. If parenteral aminopenicillin without beta-lactamase inhibitor is needed, IV ampicillin is the more practical option in Indian practice.

Fixed-dose combinations (FDCs):

FDC	Strengths Available	Notes
FDC with Clavulanic acid (Co-amoxiclav / Amoxicillin-Clavulanate)	Tablets: 375 mg (250+125), 625 mg (500+125), 1000 mg (875+125). Dry syrup: various paediatric strengths. Injection: 600 mg (500+100), 1.2 g (1000+200).	⚠️ This is a SEPARATE DRUG with a separate monograph. Covered separately. Extremely widely prescribed in India — often inappropriately when amoxicillin alone would suffice. The clavulanic acid component adds beta-lactamase inhibition → extends spectrum to include penicillinase-producing organisms (S. aureus, H. influenzae beta-lactamase-positive, M. catarrhalis, many anaerobes). ℹ️ Antimicrobial stewardship message: For many common community-acquired infections where beta-lactamase-producing organisms are NOT likely (e.g., uncomplicated GAS pharyngitis, uncomplicated community-acquired UTI due to susceptible E. coli, H. pylori eradication), amoxicillin alone is sufficient. Adding clavulanic acid unnecessarily broadens spectrum, increases GI side effects (especially diarrhoea), increases cost, and contributes to resistance selection.
FDC with Proton Pump Inhibitors and Clarithromycin (H. pylori kits)	Various “H. pylori eradication kits” containing amoxicillin 1 g + clarithromycin 500 mg + omeprazole/lansoprazole/pantoprazole in a single blister pack (BD × 14 days)	Available from multiple manufacturers. Convenient packaging improves adherence for the 14-day triple therapy regimen. CDSCO-approved.
FDC with Cloxacillin	Amoxicillin 250 mg + Cloxacillin 250 mg (capsules)	⚠️ Rationality is debated. The combination theoretically provides gram-positive (streptococcal) + anti-staphylococcal coverage. However, if staphylococcal cover is needed, amoxicillin-clavulanate is pharmacologically superior (clavulanate inhibits the beta-lactamase directly). Some Indian prescribers use this FDC but its rational basis is weak compared to amoxicillin-clavulanate. The combination is available but NOT widely recommended in standard guidelines.

⛔ Banned formulations: Various irrational FDCs containing amoxicillin with multiple other drugs (e.g., combinations with bromhexine, levofloxacin, or enzyme preparations) have been included in CDSCO FDC ban notifications over the years. Prescribers should verify the approval status of any amoxicillin-containing FDC against the latest CDSCO gazette notifications.

PHARMACOKINETICS

Primary pharmacokinetic parameters:

Parameter	Value
Bioavailability (oral)	✅ ~80–90% — excellent. Among the highest of all beta-lactam antibiotics. Absorption is rapid and nearly complete from the upper small intestine. ℹ️ This high bioavailability means that oral amoxicillin achieves serum concentrations comparable to parenteral ampicillin at equivalent doses — a key clinical advantage that often eliminates the need for IV therapy in non-critically ill patients.
Tmax	Approximately 1–2 hours after oral administration (capsules and tablets). Suspension may have slightly faster Tmax (~1 hour).
Protein binding	Approximately 17–20% (low). Mostly to albumin. Low protein binding means: (a) free drug fraction is high → good tissue penetration; (b) changes in albumin levels (liver disease, nephrotic syndrome, malnutrition) do NOT significantly alter free drug levels.
Volume of distribution (Vd)	Approximately 0.3–0.4 L/kg (moderate — distributes primarily in extracellular fluid). Penetrates well into: respiratory tract secretions, sinus mucosa, middle ear fluid, tonsils, lung tissue, peritoneal fluid, bile, uterine tissue, skin, and soft tissues. ⚠️ Does NOT penetrate CSF adequately — even with inflamed meninges, CSF penetration is insufficient for meningitis treatment at standard oral doses. IV ampicillin (not amoxicillin) is used for CNS infections (e.g., Listeria meningitis).
Metabolism	Minimal hepatic metabolism (~10–30%). Partially hydrolysed to penicilloic acid (inactive). ⛔ No CYP450 involvement. Amoxicillin is NOT a substrate, inhibitor, or inducer of any CYP450 enzyme. This is a significant clinical advantage — extremely few pharmacokinetic drug interactions. Drug transporter relevance: Amoxicillin is a substrate of OAT1 and OAT3 (organic anion transporters) in the renal tubule → mediates active tubular secretion. Also a substrate of PEPT1 and PEPT2 (peptide transporters) in the intestinal epithelium → contributes to the high oral absorption. Weak substrate of P-glycoprotein (clinically insignificant). No significant OATP, BCRP, or OCT interactions.
Active metabolites	None. Penicilloic acid is pharmacologically inactive.
Half-life (t½)	1–1.5 hours (short — similar to other penicillins). ⚠️ Prolonged in renal impairment: up to 7–20 hours in severe CKD (eGFR <10 mL/min) and anuric patients. Prolonged in neonates: 3–4 hours in term neonates (first week of life); 6–8 hours in preterm neonates.
Excretion	Primarily renal — approximately 60–70% excreted unchanged in the urine (via glomerular filtration + active tubular secretion via OAT1/OAT3). Approximately 10–25% in faeces. Small amount in bile (~5–10%).
Dialysability	✅ YES — removed by haemodialysis. A supplemental dose is recommended after each HD session. Also partially removed by peritoneal dialysis (less efficiently). See RENAL ADJUSTMENT.
Food effect	✅ Clinically insignificant. Unlike phenoxymethylpenicillin and ampicillin, amoxicillin absorption is NOT significantly reduced by food. The rate of absorption may be slightly delayed (Tmax shifted by ~30 minutes) but the extent (total AUC) is unchanged. May be taken with or without food. This food independence is a major practical advantage — patients can take it with meals, reducing GI upset without sacrificing efficacy.
Onset of action	Bactericidal activity begins as soon as therapeutic tissue concentrations are achieved — approximately 30–60 minutes after oral administration.
Duration of action	6–8 hours per dose (based on time above MIC for typical pathogens). This allows TDS (every 8 hours) dosing for most indications. For organisms with very low MICs (GAS — MIC ~0.01 mcg/mL), BD (every 12 hours) dosing is adequate (fT>MIC is maintained for >50% of the dosing interval even with BD dosing).

Pharmacodynamic note — Time-dependent killing:

ℹ️ Like all beta-lactams, amoxicillin exhibits time-dependent bactericidal activity. The key PD parameter is %fT>MIC — percentage of the dosing interval during which free drug concentration exceeds the MIC. Optimal killing requires fT>MIC ≥40–50% for penicillins.

Clinical implications for dosing frequency:

For organisms with low MICs (GAS: MIC ~0.01 mcg/mL; S. pneumoniae [susceptible]: MIC ≤2 mcg/mL for non-meningeal infections): BD dosing (every 12 hours) achieves adequate fT>MIC. This is why 1 g BD or 500 mg BD dosing is effective for pharyngitis and uncomplicated pneumonia.
For organisms with higher MICs (gram-negatives with MIC 4–8 mcg/mL, or intermediate-resistant pneumococcus): TDS dosing (every 8 hours) or high-dose BD (875 mg–1 g BD) is needed to maintain fT>MIC above the threshold.
High-dose amoxicillin (80–90 mg/kg/day in children; 1 g TDS or 875 mg BD in adults) is specifically used to overcome penicillin-intermediate S. pneumoniae — the higher dose raises the fT>MIC above the revised CLSI non-meningeal susceptibility breakpoint of ≤2 mcg/mL.

Non-linear PK: Not clinically significant at standard doses. Absorption is nearly complete at all therapeutic doses (250 mg to 1 g). At very high single doses (>2 g), absorption may approach a plateau (theoretical saturation of PEPT1 intestinal transporter), but this is rarely clinically relevant.

Population Pharmacokinetic Notes:

Population	PK Consideration
Elderly (≥60 years)	Reduced renal function → reduced clearance → modestly prolonged half-life. At standard oral doses (500 mg TDS), this is usually NOT clinically significant unless eGFR <30 (then formal dose adjustment is needed).
Paediatric	Neonates: Half-life prolonged (3–4 hours in term; 6–8 hours in preterm) due to immature renal tubular secretion. Dose interval extension needed. Infants (1–6 months): Half-life approximately 2–3 hours. Children (>6 months): Half-life similar to adults (~1–1.5 hours). Clearance per kg is similar to or slightly higher than adults — standard weight-based dosing (25–90 mg/kg/day) applies.
Pregnancy	Increased renal blood flow and GFR during pregnancy → increased amoxicillin clearance → lower steady-state levels at standard doses. For most indications, this is clinically insignificant (standard doses remain effective). For H. pylori eradication in pregnancy (rare scenario), standard dosing is maintained.
Obesity	Low Vd (~0.3–0.4 L/kg) — distributes primarily in extracellular water. In significantly obese patients, dosing based on ideal body weight is generally appropriate for standard fixed oral doses. For serious infections in morbidly obese patients, higher doses (1 g TDS) may be warranted — clinical judgement applies.
Renal impairment	⚠️ Significant. 60–70% renal excretion as unchanged drug. In severe CKD (eGFR <10), half-life increases to 7–20 hours. Dose reduction or interval extension is required. See RENAL ADJUSTMENT.
Hepatic impairment	Minimal hepatic metabolism (~10–30%). No dose adjustment required for hepatic impairment alone.
Critical illness / ICU	Amoxicillin is primarily an oral drug and is less commonly used in ICU settings (IV ampicillin or IV amoxicillin-clavulanate are preferred for parenteral therapy). If oral amoxicillin is used in an ICU patient (e.g., step-down from IV), absorption may be variable due to impaired GI function (ileus, oedema, vasopressor use). Consider parenteral alternatives in critically ill patients with uncertain GI absorption.

ADULT INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

⛔ This section is a clinical reference for qualified prescribers only. Not for self-medication or patient self-dosing.

⚠️ OVERARCHING ANTIMICROBIAL STEWARDSHIP PRINCIPLES FOR AMOXICILLIN:

Amoxicillin is NOT effective against penicillinase-producing Staphylococcus aureus — which represents >90% of community S. aureus isolates in India. For suspected staphylococcal infections (purulent cellulitis, abscess, wound infection), use cloxacillin or amoxicillin-clavulanate instead.
Amoxicillin alone vs amoxicillin-clavulanate: For many common community infections in India (GAS pharyngitis, uncomplicated pneumonia, H. pylori eradication, uncomplicated cystitis with susceptible organism), amoxicillin alone is sufficient. Adding clavulanic acid unnecessarily increases GI side effects (particularly diarrhoea), broadens spectrum, increases cost, and contributes to resistance. Reserve amoxicillin-clavulanate for infections where beta-lactamase-producing organisms are likely (animal bites, chronic sinusitis, recurrent AOM, aspiration pneumonia, complicated UTI, diabetic foot infections).
Rising resistance in India: E. coli resistance to amoxicillin in India is >60–70% (ICMR AMR data). Amoxicillin is therefore NOT recommended as empirical therapy for urinary tract infections in most Indian centres — use nitrofurantoin (for uncomplicated cystitis) or a culture-guided approach. However, if culture confirms amoxicillin-susceptible E. coli, amoxicillin is an appropriate directed therapy (narrow spectrum — stewardship advantage).
Salmonella typhi resistance: Amoxicillin was historically first-line for enteric fever in India. Due to widespread resistance, amoxicillin is no longer recommended for empirical treatment of enteric fever — use ceftriaxone or azithromycin based on current ICMR/AIIMS protocols.
Duration matters: For many indications, shorter courses (5–7 days) are now evidence-based and equally effective as longer courses (10–14 days). However, for GAS pharyngitis (RF prevention), the 10-day course is NON-NEGOTIABLE — shorter courses do not reliably eradicate GAS and do not prevent RF.

Primary Indications (Approved / Standard in India)

1. GROUP A STREPTOCOCCAL (GAS) PHARYNGITIS / TONSILLITIS — TREATMENT (Primary RF Prevention)

Clinical context: Alongside phenoxymethylpenicillin, amoxicillin is the recommended first-line antibiotic for GAS pharyngitis. In Indian practice, amoxicillin has largely replaced phenoxymethylpenicillin for this indication due to superior bioavailability, food independence, better palatability of paediatric suspensions, and simpler dosing (BD vs QID). GAS has NEVER developed resistance to amoxicillin (or any penicillin) — MICs remain at ~0.01–0.03 mcg/mL worldwide.

Dosing — Adults and Adolescents (≥12 years):

Route	Dose	Frequency	Duration	Clinical Notes
Oral	500 mg per dose	BD (every 12 hours) — PREFERRED in current practice for compliance	10 days — full course MUST be completed	ℹ️ Total daily dose: 1 g/day. BD dosing achieves comparable GAS eradication to TDS dosing and significantly improves adherence. IAP 2017 Guidelines, WHO, and AHA accept BD dosing for GAS pharyngitis treatment.
Oral (alternative)	250 mg per dose	TDS (every 8 hours) — traditional regimen	10 days	Total daily dose: 750 mg/day. Traditional regimen — pharmacologically sound but adherence is inferior to BD dosing.
Oral (high-dose — for recurrent GAS or when higher tissue levels desired)	750 mg–1 g per dose	BD	10 days	Used by some Indian clinicians for recurrent GAS pharyngitis. Evidence base for high-dose amoxicillin specifically for pharyngitis is limited — standard dosing is adequate for GAS (extremely low MIC).

⚠️ 10-day course is NON-NEGOTIABLE for RF prevention. Shorter courses (3, 5, or 7 days) do NOT reliably eradicate GAS from the pharynx and do NOT reliably prevent RF. This is the single most important counselling message.

Mandatory Clinical Notes:

When to prefer this drug over alternatives:
- Preferred over phenoxymethylpenicillin for most patients in Indian practice because: (a) better oral bioavailability (~80–90% vs ~60%); (b) NO food restriction (can take with meals — simpler for patients); © excellent palatability of paediatric suspension (strawberry/banana flavoured — much better accepted by children than bitter penicillin V suspension); (d) simpler dosing (BD vs QID); (e) wider availability in Indian pharmacies.
- Phenoxymethylpenicillin retains a niche advantage in antimicrobial stewardship (narrower spectrum — no gram-negative coverage), but this advantage is clinically marginal for an infection caused by GAS (which is exquisitely susceptible to both drugs).
- ℹ️ Single-dose IM benzathine penicillin (1.2 MU for adults; 600,000 IU for children <27 kg) remains an alternative when compliance with a 10-day oral course is uncertain.
When NOT to use:
- ⛔ Penicillin allergy (IgE-mediated) — use azithromycin (500 mg OD × 5 days) or clarithromycin (250 mg BD × 10 days). For non-anaphylactic penicillin allergy: cephalexin (500 mg BD × 10 days) may be used.
- ⚠️ Do NOT prescribe for viral pharyngitis — antibiotics provide no benefit and drive resistance. Use Centor/McIsaac scoring (≥3 criteria) or RADT for GAS to guide prescribing.
- ⚠️ Do NOT use amoxicillin in patients with suspected infectious mononucleosis (EBV infection) — aminopenicillins (amoxicillin, ampicillin) cause a characteristic maculopapular rash in ~70–100% of mononucleosis patients. This is NOT an IgE-mediated allergy — it is a virus-drug interaction (the mechanism involves polyclonal B-cell activation generating anti-aminopenicillin antibodies). ⚠️ This rash does NOT predict future penicillin allergy and should NOT be documented as “penicillin allergy.” However, it can be extensive and distressing. If pharyngitis may be due to EBV: check heterophile antibody (monospot test) or send EBV serology before prescribing amoxicillin. If EBV is confirmed, use supportive care (no antibiotic needed) or, if bacterial superinfection is suspected, use a non-aminopenicillin antibiotic (azithromycin, cephalexin).
- ⚠️ Do NOT use for peritonsillar abscess (requires drainage + IV antibiotics).
NLEM India status: ✅ Listed in NLEM India 2022 — Section 6.2 (Antibacterials — Beta-lactam medicines). Capsules 250 mg/500 mg, oral suspension 125 mg/5 mL, and dispersible tablets 250 mg are listed.
Time to response: Symptom improvement (reduced sore throat, defervescence) within 24–48 hours. If no improvement by 48–72 hours: reassess diagnosis (viral pharyngitis? peritonsillar abscess? mononucleosis? non-GAS bacterial cause?).
Treatment failure criteria:
- Clinical failure: Persistent or worsening symptoms despite 48–72 hours of appropriate therapy with confirmed adherence.
- Bacteriological failure: Positive throat culture for GAS after completing full 10-day course.
- Recurrent GAS pharyngitis: ≥3 episodes in 6 months or ≥4 in 12 months → consider: (a) carrier state (asymptomatic GAS carriage with intercurrent viral pharyngitis — does NOT usually require treatment); (b) re-infection from household contacts; © co-pathogen producing beta-lactamase (switch to amoxicillin-clavulanate 875/125 mg BD × 10 days or clindamycin 300 mg TDS × 10 days); (d) IM benzathine penicillin (single dose — guarantees eradication).
Mandatory baseline investigations: Not mandatory for empirical treatment based on clinical criteria (Centor/McIsaac ≥3). RADT or throat culture recommended where available.
Specialist initiation: Not required. PHC/CHC-level prescribing is appropriate. Any registered medical practitioner can prescribe.
Indian guideline source: IAP Guidelines on Acute Pharyngitis and RF Prevention (2017); API Textbook of Medicine (current edition); ICMR Guidelines on RF/RHD Prevention; WHO RF Prevention Guidelines.
Key safety warning: ⚠️ EBV-associated aminopenicillin rash — see point 2 above. In a young adult with pharyngitis, tonsillar enlargement, cervical lymphadenopathy, and fatigue: consider mononucleosis before prescribing amoxicillin. Check monospot or EBV serology. ⚠️ Complete the 10-day course — premature discontinuation is the most common reason for failure of RF prevention in India.
Dose adjustment: No renal/hepatic adjustment needed for a 10-day course at standard doses in patients with normal organ function. For severe CKD (eGFR <30): reduce to 250 mg BD and extend interval.

2. COMMUNITY-ACQUIRED PNEUMONIA (CAP) — MILD-TO-MODERATE (CURB-65 Score 0–1)

Clinical context: Amoxicillin is the recommended first-line antibiotic for mild, non-severe CAP (outpatient management) where Streptococcus pneumoniae is the most likely pathogen. Current Indian guidelines (API Textbook, ICMR) and international guidelines (BTS, NICE, IDSA/ATS) recommend amoxicillin for low-risk CAP. ℹ️ For moderate-severe CAP requiring hospitalisation, IV antibiotics (ceftriaxone + azithromycin) are standard — see ceftriaxone monograph.

Dosing — Adults:

Route	Dose	Frequency	Duration	Clinical Notes
Oral (standard dose)	500 mg per dose	TDS (every 8 hours)	5 days (if clinically improving by day 3; may extend to 7 days if slower response)	Standard first-line for mild CAP. ℹ️ The 5-day course is supported by multiple RCTs (including the CAP-START trial, NICE 2019 guidance) and is now accepted as adequate for mild CAP with early clinical response.
Oral (high dose — for suspected penicillin-intermediate pneumococcus)	1 g per dose	TDS (every 8 hours)	5–7 days	⚠️ High-dose amoxicillin is recommended when penicillin-intermediate S. pneumoniae (PISP) is a concern — e.g., patients with recent antibiotic use, chronic lung disease, age >65, immunocompromised. The higher dose ensures fT>MIC exceeds the CLSI non-meningeal breakpoint of ≤2 mcg/mL for intermediate-resistant pneumococcus. ICMR AMR data suggest 3–10% penicillin-intermediate pneumococci in India (varies regionally).
Oral (alternative — BD dosing)	875 mg–1 g per dose	BD (every 12 hours)	5–7 days	For patients who cannot take TDS dosing. The higher individual dose compensates for the extended interval, maintaining adequate fT>MIC for susceptible organisms.

ℹ️ When to add macrolide coverage for atypical pathogens:

If atypical pneumonia is clinically suspected (dry cough, interstitial infiltrates on X-ray, young adult, outbreaks, exposure history for Legionella or Mycoplasma) or if the patient has risk factors for dual typical + atypical infection: add azithromycin 500 mg OD × 3–5 days or doxycycline 100 mg BD × 5–7 days to amoxicillin.
Amoxicillin alone does NOT cover Mycoplasma pneumoniae, Chlamydophila pneumoniae, or Legionella pneumophila.
API Textbook recommends amoxicillin ± macrolide for mild CAP based on clinical judgement regarding atypical pathogen likelihood.

Mandatory Clinical Notes:

When to prefer over alternatives:
- Amoxicillin is the narrowest effective spectrum oral antibiotic for pneumococcal CAP — preferred over amoxicillin-clavulanate, fluoroquinolones, or cephalosporins for mild outpatient CAP as an antimicrobial stewardship principle.
- Preferred over azithromycin monotherapy for CAP in India because: (a) pneumococcal azithromycin resistance is rising in India (~10–20% in some regions per ICMR AMR data); (b) amoxicillin reliably kills pneumococcus at achievable serum/tissue concentrations; © azithromycin does not cover pneumococcus as reliably as a beta-lactam.
- ⚠️ Respiratory fluoroquinolones (levofloxacin, moxifloxacin) should be RESERVED for CAP treatment failure, penicillin allergy, or moderate-severe CAP — they are NOT first-line for mild outpatient CAP. Overuse of fluoroquinolones in India is a major antimicrobial stewardship concern and also masks underlying TB (both fluoroquinolones have anti-TB activity, leading to delayed TB diagnosis).
When NOT to use:
- ⚠️ Moderate-severe CAP (CURB-65 ≥2, requiring hospitalisation) — amoxicillin alone is inadequate. Use IV ceftriaxone + azithromycin (or IV amoxicillin-clavulanate + azithromycin).
- ⚠️ Aspiration pneumonia — polymicrobial including anaerobes → use amoxicillin-clavulanate (or clindamycin).
- ⚠️ Hospital-acquired pneumonia (HAP) / ventilator-associated pneumonia (VAP) — different pathogen profile → not covered by amoxicillin.
- ⚠️ Suspected TB — ⛔ Do NOT treat suspected pulmonary TB with amoxicillin. Amoxicillin may provide partial symptomatic improvement in TB (weak anti-mycobacterial activity + treatment of secondary bacterial infection) → delays TB diagnosis and promotes drug resistance. If TB is a differential: send sputum for AFB/GeneXpert before starting empirical antibiotics, or treat for TB (not for CAP).
NLEM status: ✅ Amoxicillin is NLEM-listed.
Time to response: Clinical improvement (reduced fever, improving cough, reduced dyspnoea) within 48–72 hours. If no improvement by 72 hours: reassess (chest X-ray, sputum culture, consider TB, consider broadening antibiotic coverage to amoxicillin-clavulanate or adding macrolide, consider hospitalisation if deteriorating).
Treatment failure criteria: Persistent fever >72 hours; worsening dyspnoea; new or spreading infiltrates on repeat CXR; haemodynamic instability. Action: hospitalise, obtain cultures (blood, sputum), switch to IV antibiotics (ceftriaxone + azithromycin).
Mandatory baseline investigations:
- MANDATORY: Chest X-ray (PA view) — to confirm pneumonia and exclude TB, malignancy, effusion, abscess.
- RECOMMENDED: SpO₂ (pulse oximetry — if <94% on room air, consider hospitalisation). CURB-65 scoring (Confusion, Urea >7 mmol/L, Respiratory rate ≥30, BP systolic <90 or diastolic ≤60, age ≥65). CBC, CRP (to guide severity and response). Sputum Gram stain and culture (where available). Sputum AFB/GeneXpert (if TB is a differential — MANDATORY in India where TB prevalence is high).
- ⚠️ India-specific: In any patient with cough >2 weeks, weight loss, night sweats, or haemoptysis: rule out TB before diagnosing as CAP. This is a critical public health imperative.
Specialist initiation: Not required for mild outpatient CAP. PHC/CHC-level prescribing is appropriate. Refer if: no response by 72 hours, SpO₂ <94%, CURB-65 ≥2, suspected complications (effusion, abscess, empyema), or suspected TB.
Indian guideline source: API Textbook of Medicine (current edition) — chapter on Pneumonia; ICMR Treatment Guidelines for common infections; BTS CAP Guidelines (adapted for India); NICE Pneumonia Guidelines (2019 — endorsed shorter courses).
Key safety warning: ⚠️ Always consider TB in any Indian patient with pneumonia symptoms, especially if: cough >2 weeks, weight loss, haemoptysis, upper lobe infiltrate, cavitation, history of TB contact, HIV-positive. Amoxicillin is NOT a treatment for TB. Using amoxicillin for presumed “CAP” in a patient who actually has TB delays diagnosis by weeks and contributes to TB transmission.
Dose adjustment: For standard 5–7 day CAP course: reduce dose if eGFR <30 (see RENAL ADJUSTMENT). No hepatic adjustment needed.

3. ACUTE OTITIS MEDIA (AOM)

Clinical context: Amoxicillin is the first-line antibiotic for AOM in India (IAP guidelines). The most common pathogens are S. pneumoniae, H. influenzae (non-typeable — ~30–40% produce beta-lactamase), and Moraxella catarrhalis (~90% produce beta-lactamase). Despite the beta-lactamase prevalence, amoxicillin remains first-line because: (a) S. pneumoniae is the most common pathogen and is penicillin-susceptible; (b) many H. influenzae AOM episodes resolve spontaneously; © high-dose amoxicillin overcomes intermediate pneumococcal resistance.

Dosing — Adults:

Route	Dose	Frequency	Duration	Clinical Notes
Oral (standard dose)	500 mg per dose	TDS	5–7 days (for uncomplicated AOM in adults; shorter course is acceptable for mild cases with early response)	Standard regimen for adult AOM.
Oral (high dose)	875 mg–1 g per dose	BD	5–7 days	For suspected penicillin-intermediate pneumococcus or recent antibiotic use (within 30 days — risk factor for resistant organisms).

ℹ️ AOM in adults is uncommon compared to children — see PAEDIATRIC DOSING for the primary paediatric AOM dosing (where high-dose amoxicillin 80–90 mg/kg/day is the standard).

Mandatory Clinical Notes:

When to prefer over alternatives: First-line for uncomplicated AOM. Preferred over amoxicillin-clavulanate for INITIAL therapy — reserve co-amoxiclav for treatment failure (persistent symptoms after 48–72 hours of amoxicillin), recurrent AOM, or patients who received amoxicillin within the past 30 days.
When NOT to use: AOM with TM perforation and purulent otorrhoea — add topical antibiotic drops (ciprofloxacin/ofloxacin otic). Chronic suppurative otitis media (CSOM) — different pathogen profile, requires ENT evaluation and typically topical therapy ± systemic antibiotics targeting Pseudomonas and anaerobes. Suspected mastoiditis — requires hospitalisation, IV antibiotics, and ENT consultation.
NLEM status: ✅ NLEM-listed.
Time to response: Improvement in ear pain and fever within 48–72 hours.
Treatment failure: Persistent symptoms after 48–72 hours → switch to amoxicillin-clavulanate (875/125 mg BD) OR cefuroxime axetil (500 mg BD). ENT referral for recurrent AOM (≥3 in 6 months or ≥4 in 12 months) — consider tympanostomy tubes.
Baseline investigations: Otoscopy (MANDATORY). No lab tests needed for uncomplicated AOM. Tympanometry if available.
Specialist initiation: Not required. PHC-level prescribing appropriate.
Indian source: IAP Guidelines on AOM Management; API Textbook of Medicine; ENT standard practice.
Safety warning: ⚠️ Do NOT miss mastoiditis — if postauricular swelling, tenderness, or forward displacement of the pinna is present, this is a surgical emergency requiring IV antibiotics and ENT referral. Do NOT treat with oral amoxicillin alone.
Dose adjustment: Standard adjustments apply.

4. ACUTE BACTERIAL RHINOSINUSITIS

Clinical context: Amoxicillin (or amoxicillin-clavulanate) is the first-line antibiotic for acute bacterial rhinosinusitis (ABRS) when antibiotic therapy is indicated. ⚠️ Most acute sinusitis is viral and does NOT require antibiotics. Antibiotics are indicated only for: (a) symptoms lasting ≥10 days without improvement; (b) severe onset (high fever ≥39°C + purulent nasal discharge ≥3 days); © worsening after initial improvement (“double sickening”).

Dosing — Adults:

Route	Dose	Frequency	Duration	Clinical Notes
Oral (standard)	500 mg per dose	TDS	5–7 days (shorter courses are now accepted — IDSA/NICE/ACP guidelines support 5-day courses for uncomplicated ABRS)	For uncomplicated ABRS without risk factors for resistance.
Oral (high dose)	875 mg–1 g per dose	BD or TDS	7–10 days	For patients with: recent antibiotic use (within 30 days), daycare exposure (children), severe symptoms, immunocompromised, or geographic region with high pneumococcal resistance. API Textbook and IDSA recommend high-dose amoxicillin or amoxicillin-clavulanate for moderate-severe ABRS.

ℹ️ Amoxicillin vs amoxicillin-clavulanate for sinusitis:

IDSA 2012 Guidelines recommend amoxicillin-clavulanate (not amoxicillin alone) as first-line for ABRS, citing the need for H. influenzae and M. catarrhalis coverage (both commonly produce beta-lactamase).
Other guidelines (AAP, NICE, some Indian ENT practice) accept amoxicillin alone for uncomplicated, mild ABRS as initial therapy.
Indian practice varies: Many Indian ENT specialists and GPs prescribe amoxicillin-clavulanate as first-line for sinusitis. Amoxicillin alone is acceptable for INITIAL therapy of mild ABRS; step up to amoxicillin-clavulanate if no response within 72 hours.

Mandatory Clinical Notes:

When to prefer: For initial empirical therapy of mild, uncomplicated ABRS without risk factors for resistance. Narrower spectrum than amoxicillin-clavulanate.
When NOT to use: Chronic rhinosinusitis (>12 weeks) — different pathogen profile, requires ENT evaluation. Complicated sinusitis (orbital cellulitis, frontal subperiosteal abscess, intracranial extension) — requires hospitalisation and IV antibiotics. Allergic/fungal sinusitis — antibiotics not indicated.
NLEM status: ✅ NLEM-listed.
Time to response: Improvement within 3–5 days. If no response by day 3–5: switch to amoxicillin-clavulanate or doxycycline; consider imaging (CT sinuses); consider ENT referral.
Indian source: API Textbook of Medicine; Indian ENT specialist practice; adapted from IDSA Sinusitis Guidelines (2012).
Safety warning: ⚠️ Distinguish bacterial from viral sinusitis before prescribing antibiotics. The vast majority of acute sinusitis episodes are viral and resolve spontaneously. Unnecessary antibiotic prescribing for viral sinusitis is a major AMR driver in India. Duration criteria (≥10 days without improvement), severity criteria, or “double sickening” should guide the decision to prescribe.

5. HELICOBACTER PYLORI ERADICATION — AS PART OF COMBINATION THERAPY

Clinical context: Amoxicillin is a core component of most H. pylori eradication regimens. Unlike many antibiotics, H. pylori resistance to amoxicillin remains very low globally and in India (<2%) — making it a reliable partner drug in all combination regimens.

Dosing — Adults (within combination regimens):

Regimen	Amoxicillin Dose	Other Components	Duration	Notes
Standard Triple Therapy	1 g BD	+ PPI (standard dose BD) + Clarithromycin 500 mg BD	14 days	⚠️ Clarithromycin resistance in India is rising (~15–30% in some regions per Indian studies). Standard triple therapy is losing efficacy where clarithromycin resistance exceeds 15%. However, it remains the most commonly prescribed regimen in Indian outpatient practice. 14-day duration is superior to 7-day or 10-day courses.
Bismuth Quadruple Therapy	1 g BD	+ PPI (standard dose BD) + Bismuth subsalicylate/subcitrate 525 mg QID + Metronidazole 500 mg TDS (or Tetracycline 500 mg QID)	14 days	⚠️ Bismuth preparations have limited availability in India. Where available, quadruple therapy is effective even in clarithromycin-resistant areas.
Concomitant (Non-Bismuth) Quadruple Therapy	1 g BD	+ PPI (standard dose BD) + Clarithromycin 500 mg BD + Metronidazole 500 mg BD	14 days	Higher eradication rates than standard triple therapy (~85–90% vs ~70–80%). Increasing use in Indian gastroenterology practice.
Sequential Therapy	1 g BD (days 6–10 or 6–14)	Days 1–5: PPI BD + Amoxicillin 1 g BD. Days 6–10 (or 6–14): PPI BD + Clarithromycin 500 mg BD + Metronidazole 500 mg BD	10–14 days	Sequencing aims to overcome clarithromycin resistance. Moderate evidence; not universally adopted.
Levofloxacin-Based Triple Therapy (Rescue/Second-Line)	1 g BD	+ PPI (standard dose BD) + Levofloxacin 500 mg OD	14 days	⚠️ Used as rescue/second-line after failure of first-line regimen. Levofloxacin resistance in India is also rising. Reserve for treatment failure.

Mandatory Clinical Notes:

When to prefer amoxicillin-based regimens: Amoxicillin is used in virtually ALL H. pylori eradication regimens because of its consistently low resistance rate (<2%). It is the one constant across regimens — the choice between regimens depends on the partner drug (clarithromycin vs metronidazole vs levofloxacin) and local resistance patterns.
When NOT to use: ⛔ Penicillin allergy — use clarithromycin-based (without amoxicillin) or metronidazole-based quadruple therapy. Levofloxacin + PPI + bismuth + metronidazole is an amoxicillin-free rescue regimen.
NLEM status: ✅ Amoxicillin is NLEM-listed. PPIs (omeprazole, pantoprazole) are also NLEM-listed.
Time to response: Symptom improvement (dyspepsia, epigastric pain): 1–4 weeks after completing the eradication course. ⚠️ Confirm eradication with a non-invasive test (urea breath test or stool antigen test) at least 4 weeks after completing the antibiotic course AND at least 2 weeks after stopping PPI. Testing too early or while on PPI gives false negatives.
Treatment failure: If first-line triple therapy fails: use a different regimen that does NOT repeat the same antibiotics (e.g., if clarithromycin-based triple failed, use levofloxacin-based triple or bismuth quadruple). Do NOT simply repeat the same failed regimen.
Baseline investigations:
- MANDATORY: Confirmed H. pylori diagnosis before treatment — by endoscopy (CLO test, histology), or non-invasive testing (urea breath test, stool antigen test, or serological testing). ⚠️ Do NOT prescribe empirical H. pylori eradication without confirmed diagnosis — this is inappropriate antibiotic use.
- RECOMMENDED: Upper GI endoscopy for patients with alarm features (age >45 with new-onset dyspepsia, weight loss, dysphagia, GI bleeding, anaemia, persistent vomiting).
Specialist initiation: Not required for confirmed uncomplicated H. pylori infection treated with standard first-line regimen. Gastroenterology referral for: treatment failure, recurrent infection, complicated peptic ulcer disease, MALT lymphoma.
Indian source: API Textbook of Medicine — chapter on Peptic Ulcer Disease and H. pylori; Indian Society of Gastroenterology (ISG) guidelines on H. pylori management; Maastricht VI / Florence Consensus adapted for India.
Safety warning: ⚠️ Antibiotic resistance in India is the primary reason for H. pylori treatment failure. Clarithromycin resistance (~15–30%) and metronidazole resistance (~80–90%) are both high in India. Despite this, metronidazole-based regimens can still work at higher doses (500 mg TDS–QID) for partial resistance. Culture and susceptibility testing (limited availability in India) should be considered after second-line failure.
Dose adjustment: Standard renal adjustment applies for amoxicillin component (reduce if eGFR <30). No hepatic adjustment.

6. URINARY TRACT INFECTIONS — DIRECTED THERAPY (Culture-Guided Only)

Clinical context: ⚠️ Amoxicillin is NOT recommended for EMPIRICAL treatment of UTI in India due to high E. coli resistance rates (>60–70% per ICMR AMR surveillance data). However, if urine culture confirms an amoxicillin-susceptible organism (susceptible E. coli, Enterococcus faecalis, Proteus mirabilis), amoxicillin is an appropriate directed therapy choice — its narrow spectrum is an antimicrobial stewardship advantage over fluoroquinolones and cephalosporins.

Dosing — Adults:

Condition	Route	Dose	Frequency	Duration	Notes
Uncomplicated cystitis (confirmed susceptible)	Oral	500 mg per dose	TDS	3–5 days (women); 7 days (men)	ℹ️ Empirical first-line for uncomplicated cystitis in India: nitrofurantoin 100 mg BD × 5 days (NLEM-listed, low resistance). Amoxicillin: directed therapy only.
Uncomplicated pyelonephritis (confirmed susceptible, mild)	Oral	500 mg–1 g per dose	TDS	7–14 days	⚠️ Only for mild pyelonephritis in ambulatory patients with confirmed susceptibility. Moderate-severe pyelonephritis requires IV antibiotics (ceftriaxone or aminoglycoside).
UTI in pregnancy (confirmed susceptible)	Oral	500 mg per dose	TDS	7 days	ℹ️ Amoxicillin is safe in pregnancy and is a preferred antibiotic for UTI in pregnancy IF the organism is susceptible. Nitrofurantoin is the usual empirical first-line for uncomplicated cystitis in pregnancy (avoid in first trimester and at term per some guidelines — Indian obstetric practice varies).
Asymptomatic bacteriuria in pregnancy (confirmed susceptible)	Oral	500 mg per dose	TDS	7 days	Treatment of asymptomatic bacteriuria is MANDATORY in pregnancy (reduces risk of pyelonephritis and preterm birth).

Mandatory Clinical Notes:

When to prefer: ONLY when culture confirms amoxicillin-susceptible organism. Narrower spectrum than fluoroquinolones or cephalosporins — stewardship advantage. Preferred for susceptible Enterococcus faecalis UTI (enterococci are intrinsically resistant to cephalosporins — amoxicillin or ampicillin are the drugs of choice for susceptible enterococcal UTI).
When NOT to use: ⛔ NEVER use empirically for UTI in India — resistance rates are too high. ⛔ NOT effective against Klebsiella, Pseudomonas, or ESBL-producing organisms. ⛔ NOT effective for catheter-associated UTI (CAUTI) empirically.
NLEM status: ✅ NLEM-listed (amoxicillin). Nitrofurantoin is also NLEM-listed and is the preferred empirical first-line for uncomplicated cystitis.
Indian source: ICMR Treatment Guidelines for Antimicrobial Use; ICMR AMR Surveillance Data; API Textbook of Medicine.
Safety warning: ⚠️ AMR in India: Empirical use of amoxicillin for UTI in India will fail in >60% of cases due to E. coli amoxicillin resistance. This results in treatment failure, prolonged patient suffering, additional healthcare visits, and potential progression to pyelonephritis/sepsis. Prescribe empirical amoxicillin for UTI ONLY if culture/sensitivity testing is completely unavailable AND nitrofurantoin is also unavailable — and follow up with culture results to adjust therapy.

7. DENTAL INFECTIONS — MILD-TO-MODERATE

Dosing — Adults:

Route	Dose	Frequency	Duration	Notes
Oral	500 mg per dose	TDS	5–7 days	For mild dental infections (periapical abscess — early, dental cellulitis, post-extraction infection). ⚠️ Most dental infections are mixed aerobic-anaerobic → add metronidazole 400 mg TDS for anaerobic cover if clinically indicated (significant swelling, trismus, deep space involvement). ⚠️ Drainage is the primary treatment for dental abscesses — antibiotics alone are inadequate without drainage/extraction.

8. INFECTIVE ENDOCARDITIS — ANTIBIOTIC PROPHYLAXIS (Dental Procedures)

Clinical context: Amoxicillin is the recommended antibiotic for endocarditis prophylaxis before dental procedures in patients at high risk of IE. ℹ️ Current guidelines restrict prophylaxis to high-risk patients only — prosthetic heart valves, previous IE, certain congenital heart defects, cardiac transplant with valvulopathy. Prophylaxis is NO LONGER recommended for “intermediate-risk” patients (native valve disease, RHD without prosthetic valve, mitral valve prolapse with regurgitation).

⚠️ Indian practice note: Despite updated guidelines restricting prophylaxis to high-risk groups, many Indian cardiologists and dentists continue to prescribe prophylaxis for patients with RHD (including those without prosthetic valves). This is a reasonable approach given the extremely high burden of RHD in India and the low risk of a single amoxicillin dose. API Textbook of Medicine discusses this nuanced approach. AIIMS protocol tends to follow AHA guidelines (high-risk only); some other Indian centres cast a wider net.

Dosing — Adults:

Route	Dose	Timing	Clinical Notes
Oral	2 g as a SINGLE DOSE	30–60 minutes before the dental procedure (ideally 60 minutes before)	Single dose ONLY — NO post-procedure doses are needed. Adequate serum and tissue levels are maintained for the duration of the dental procedure. If the patient cannot take oral medication: IV ampicillin 2 g or IV amoxicillin 2 g (if available), administered 30 minutes before the procedure.

For penicillin-allergic patients:

Non-anaphylactic allergy: Cephalexin 2 g oral × 1 dose (30–60 min before procedure) — ⚠️ avoid if history of anaphylaxis to penicillin.
Anaphylactic penicillin allergy: Azithromycin 500 mg oral × 1 dose (60 min before) OR Clindamycin 600 mg oral × 1 dose (30–60 min before).

Mandatory Clinical Notes:

Who receives prophylaxis (high-risk indications): (a) Prosthetic heart valves (mechanical or bioprosthetic); (b) Previous infective endocarditis; © Unrepaired cyanotic congenital heart disease; (d) Repaired CHD with residual defects at or adjacent to prosthetic material; (e) Cardiac transplant recipients with valvulopathy. ℹ️ Indian practice extension: Many Indian centres also provide prophylaxis for patients with significant RHD (moderate-severe mitral/aortic regurgitation on echocardiography) — this is a practice-based decision, not strictly evidence-based.
Which procedures require prophylaxis: Dental procedures involving gingival manipulation, periapical region, or perforation of oral mucosa (tooth extraction, periodontal procedures, implant placement, scaling with anticipated bleeding). NOT for: routine local anaesthesia injections through non-infected tissue, suture removal, dental X-rays, orthodontic bracket placement, or simple restorations above the gum line.
NLEM status: ✅ Amoxicillin is NLEM-listed.
Indian source: API Textbook of Medicine — IE chapter; AHA/ESC IE Guidelines adapted for India; AIIMS IE prophylaxis protocol.
Safety warning: ⚠️ Do NOT omit the pre-procedure dose and give it “after” the procedure — this is a common timing error. The antibiotic must be in the bloodstream BEFORE bacteraemia occurs (at the time of dental manipulation). Taking it after the procedure provides no prophylactic benefit.

9. MILD, NON-PURULENT SKIN AND SOFT TISSUE INFECTIONS (Streptococcal — Erysipelas, Non-Purulent Cellulitis)

Dosing — Adults:

Route	Dose	Frequency	Duration	Notes
Oral	500 mg per dose	TDS	5–7 days (may extend to 10 days if slow response)	For mild erysipelas and non-purulent cellulitis where Group A Streptococcus is the likely pathogen. ⚠️ For purulent cellulitis/abscess (suggesting staphylococcal aetiology): amoxicillin alone is inadequate → use cloxacillin or amoxicillin-clavulanate. Mark the erythema margin with a skin marker at baseline to objectively track progression/regression.

Secondary Indications — Adults Only (Off-label)

1. TYPHOID / ENTERIC FEVER — DIRECTED THERAPY (Culture-Confirmed Susceptible)

OFF-LABEL in current practice — formerly first-line but now replaced by ceftriaxone/azithromycin due to resistance

Route	Dose	Frequency	Duration	Notes
Oral	1 g per dose	TDS (or 750 mg QID)	14 days	⚠️ NOT for empirical treatment. Salmonella typhi amoxicillin resistance is variable in India (20–40% in some regions per ICMR AMR data). Use ONLY if culture confirms amoxicillin-susceptible S. typhi or S. paratyphi. Current empirical first-line for enteric fever in India: ceftriaxone 2 g IV OD × 10–14 days (for moderate-severe) or azithromycin 1 g OD × 7 days (for mild, uncomplicated). Amoxicillin is a valid de-escalation option after culture confirmation.

Evidence basis: Level of evidence: Moderate (historically strong; now practice-based for directed therapy after culture confirmation). API Textbook of Medicine references amoxicillin for culture-guided enteric fever treatment.

2. LYME DISEASE — EARLY (Erythema Migrans)

OFF-LABEL

ℹ️ Lyme disease is rare in India — confirmed cases have been reported from Himalayan regions (Himachal Pradesh, Uttarakhand, Northeast India) but the disease burden is very low. Treatment guidelines are adapted from IDSA/AAN recommendations.

Route	Dose	Frequency	Duration	Notes
Oral	500 mg per dose	TDS	14–21 days	Alternative to doxycycline 100 mg BD × 14–21 days. Amoxicillin is preferred over doxycycline in: (a) children <8 years (doxycycline causes tooth staining); (b) pregnant women (doxycycline is contraindicated in pregnancy).

Evidence basis: Level of evidence: Strong (multiple international RCTs; IDSA/AAN guidelines). Very limited Indian-specific data due to rarity of the disease.

3. PROPHYLAXIS OF RECURRENT URINARY TRACT INFECTIONS IN PREGNANCY

OFF-LABEL but accepted standard practice in India

Route	Dose	Frequency	Duration	Notes
Oral	250 mg per dose	OD at bedtime (low-dose prophylaxis)	Throughout pregnancy (from diagnosis of recurrent UTI until delivery)	Alternative prophylactic agents: nitrofurantoin 50 mg OD at bedtime (avoid at term — neonatal haemolysis risk), cephalexin 250 mg OD. Amoxicillin is acceptable for susceptible organisms. ⚠️ Use ONLY if cultures have confirmed amoxicillin-susceptible uropathogen in past episodes — empirical prophylaxis with amoxicillin is likely to fail due to high E. coli resistance.

Evidence basis: Level of evidence: Moderate (obstetric guideline-endorsed practice; adapted from FOGSI/ACOG recommendations).

4. ACUTE EXACERBATION OF CHRONIC BRONCHITIS / COPD (AECB)

OFF-LABEL but accepted standard practice in India

Route	Dose	Frequency	Duration	Notes
Oral	500 mg per dose	TDS	5 days	For Anthonisen Type 1 exacerbation (all 3 criteria: increased dyspnoea + increased sputum volume + sputum purulence) OR Type 2 (2 of 3 criteria, one being sputum purulence). ⚠️ NOT all COPD exacerbations require antibiotics — viral triggers are common. Amoxicillin covers S. pneumoniae and non-beta-lactamase-producing H. influenzae. For patients with frequent exacerbations, FEV₁ <50%, or recent antibiotic use: use amoxicillin-clavulanate or doxycycline instead.

Evidence basis: Level of evidence: Moderate (multiple RCTs support antibiotics for purulent COPD exacerbations; GOLD guidelines endorse amoxicillin as one option).

Indian source: API Textbook of Medicine — COPD chapter; GOLD guidelines adapted for India.

5. ACUTE INFECTIVE EXACERBATION OF BRONCHIECTASIS — MILD-TO-MODERATE (Non-Pseudomonal)

Clinical context: Bronchiectasis is highly prevalent in India — post-tubercular bronchiectasis is the most common cause, followed by post-childhood infections (measles, pertussis, severe pneumonia), allergic bronchopulmonary aspergillosis (ABPA), primary ciliary dyskinesia, and immunodeficiency. Acute infective exacerbations are characterised by increased sputum volume, sputum purulence, worsening dyspnoea, and sometimes haemoptysis and fever. The most common pathogens in acute exacerbations of non-cystic fibrosis bronchiectasis are:

Pathogen	Approximate Prevalence in Indian Bronchiectasis Studies	Amoxicillin Susceptibility
Haemophilus influenzae (non-typeable)	30–50% (most common pathogen)	⚠️ Variable — ~30–40% of Indian H. influenzae isolates produce beta-lactamase → resistant to amoxicillin alone. Susceptibility must be confirmed by culture OR empirical coverage with amoxicillin-clavulanate may be more appropriate.
Streptococcus pneumoniae	15–25%	✅ Susceptible — amoxicillin is effective (especially at high doses for intermediate resistance).
Pseudomonas aeruginosa	15–30% (higher in advanced/severe bronchiectasis, prolonged disease duration, frequent exacerbations, prior antibiotic courses)	⛔ Intrinsically resistant to amoxicillin (and amoxicillin-clavulanate). Requires anti-pseudomonal agents (ciprofloxacin, piperacillin-tazobactam, ceftazidime, meropenem).
Moraxella catarrhalis	5–10%	⚠️ Nearly all produce beta-lactamase → resistant to amoxicillin alone. Susceptible to amoxicillin-clavulanate.
Staphylococcus aureus	5–10%	⚠️ Most produce penicillinase → resistant to amoxicillin alone.
Gram-negative enterobacteriaceae (Klebsiella, E. coli)	5–15% (higher in Indian series — possibly related to TB sequelae, structural damage)	⚠️ Variable; high resistance rates in India.

ℹ️ Key clinical implication: The pathogen profile of bronchiectasis exacerbations is more complex than typical CAP — a substantial proportion of pathogens produce beta-lactamase or are intrinsically resistant to amoxicillin. This means amoxicillin alone is appropriate ONLY for a subset of bronchiectasis exacerbations — specifically those where:

Pseudomonas has NOT been previously isolated from the patient’s sputum
The exacerbation is mild-to-moderate (not requiring hospitalisation)
A recent sputum culture (if available) shows amoxicillin-susceptible organisms
The patient has NOT recently received amoxicillin (within the past 3 months — risk factor for resistance selection)

For many bronchiectasis patients in India, amoxicillin-clavulanate is the more appropriate empirical first-line choice — it covers beta-lactamase-producing H. influenzae and M. catarrhalis while retaining pneumococcal coverage. See amoxicillin-clavulanate monograph.

Dosing — Adults:

Route	Dose	Frequency	Duration	Clinical Notes
Oral (standard dose)	500 mg per dose	TDS (every 8 hours)	14 days (⚠️ longer than for typical CAP — bronchiectasis exacerbations require longer antibiotic courses due to the structural lung damage, impaired mucociliary clearance, and higher bacterial load in damaged airways)	For mild exacerbation with NO prior Pseudomonas isolation AND no recent antibiotic use AND susceptible pathogen on recent sputum culture (or where culture is not available and clinical judgement favours susceptible organisms).
Oral (high dose — for suspected penicillin-intermediate pneumococcus or when maximising tissue levels)	1 g per dose	TDS	14 days	Consider high-dose when: chronic disease, frequent exacerbations, recent standard-dose amoxicillin use (within 3 months).

ℹ️ BTS Bronchiectasis Guideline (2019) and ERS Bronchiectasis Guideline (2017) — both recommend 14 days for acute exacerbations. This is longer than the 5–7 days recommended for uncomplicated CAP. The rationale: (a) damaged airways harbour higher bacterial load; (b) impaired local immunity in bronchiectatic segments; © reduced antibiotic penetration into inspissated secretions within dilated airways; (d) relapse rates are higher with shorter courses in bronchiectasis. Some Indian pulmonologists use 10–14 days — API Textbook of Medicine does not mandate a specific duration but 14 days is standard specialist practice.

Mandatory Clinical Notes:

When to prefer amoxicillin ALONE over amoxicillin-clavulanate:
- When recent sputum culture confirms amoxicillin-susceptible pathogen (e.g., non-beta-lactamase-producing H. influenzae, susceptible S. pneumoniae) — amoxicillin alone is narrower spectrum and avoids the increased diarrhoea from clavulanic acid (important because many bronchiectasis patients are chronically unwell and clavulanate-induced diarrhoea is particularly bothersome).
- When the patient has a first or infrequent exacerbation without prior Pseudomonas isolation and without recent antibiotic exposure.
- When antimicrobial stewardship is prioritised — amoxicillin alone is narrower spectrum.
When NOT to use amoxicillin alone (use amoxicillin-clavulanate or broader coverage instead):
- ⚠️ Pseudomonas aeruginosa has been previously isolated from the patient’s sputum — even once. Once Pseudomonas colonises bronchiectatic airways, it tends to persist and is the likely pathogen in subsequent exacerbations. Use oral ciprofloxacin 500–750 mg BD × 14 days (first-line for Pseudomonal bronchiectasis exacerbation) or IV anti-pseudomonal antibiotics if severe (piperacillin-tazobactam, ceftazidime, meropenem — with or without IV aminoglycoside). ⛔ Amoxicillin (with or without clavulanate) has NO activity against Pseudomonas.
- ⚠️ Recent amoxicillin use (within the past 3 months) — risk of selection of beta-lactamase-producing H. influenzae → use amoxicillin-clavulanate instead.
- ⚠️ Frequent exacerbations (≥3 per year) — these patients often have more resistant organisms → sputum culture-guided therapy is essential. Empirically, amoxicillin-clavulanate or doxycycline is more appropriate than amoxicillin alone.
- ⚠️ Severe exacerbation requiring hospitalisation — needs IV antibiotics (amoxicillin-clavulanate IV, or ceftriaxone, or anti-pseudomonal agents if Pseudomonas is suspected).
- ⚠️ Patient with known ABPA (allergic bronchopulmonary aspergillosis) — exacerbation may be fungal, not bacterial. Check IgE levels, eosinophil count, consider itraconazole. Do NOT treat all exacerbations with antibiotics reflexively.
- ⚠️ Haemoptysis — if moderate-to-severe haemoptysis is the presenting feature of the exacerbation, the priority is haemoptysis management (bronchial artery embolisation if massive; CT angiography), not just antibiotics.
NLEM India status: ✅ Amoxicillin is NLEM-listed. However, no specific NLEM indication listing for bronchiectasis — the NLEM lists amoxicillin for “infections.”
Time to response: Reduction in sputum purulence and volume within 3–5 days. Defervescence (if febrile) within 48–72 hours. If no improvement by 5–7 days: reassess — repeat sputum culture, consider broadening coverage (amoxicillin-clavulanate, doxycycline, or fluoroquinolone), consider CT chest (rule out mycobacterial superinfection, abscess, aspergilloma).
Treatment failure criteria:
- No improvement in sputum purulence/volume by day 5–7.
- Worsening dyspnoea, new fever, or new CXR infiltrates during treatment.
- Early relapse within 2 weeks of completing the antibiotic course.
- Action: Obtain sputum culture (including AFB smear/GeneXpert — TB reactivation in post-TB bronchiectasis is common in India). Broaden antibiotic coverage based on culture results. Pulmonology referral if not already involved.
Mandatory baseline investigations:
- MANDATORY: Sputum culture and sensitivity (⚠️ BEFORE starting antibiotics) — this is more important in bronchiectasis than in CAP because: (a) recurrent infections require targeted therapy; (b) Pseudomonas isolation changes management completely; © resistance patterns vary between patients based on prior antibiotic exposure. Indian pulmonologists should maintain a “sputum culture history” for each bronchiectasis patient — documenting all previous isolates. This guides empirical therapy for future exacerbations.
- MANDATORY: Chest X-ray (PA view) — to assess for new infiltrates, effusion, abscess, or underlying TB reactivation.
- RECOMMENDED: SpO₂ (pulse oximetry). CBC, CRP (severity and response assessment). Sputum AFB smear/GeneXpert (⚠️ CRITICAL in India — reactivation of TB in post-tubercular bronchiectatic lungs is common; “purulent exacerbation” may actually be TB relapse).
- RECOMMENDED (for baseline/initial evaluation — if not previously done): HRCT chest (gold standard for bronchiectasis diagnosis and extent assessment); sputum for fungal culture (ABPA); serum IgE and eosinophil count (ABPA); immunoglobulin levels (if immunodeficiency suspected); sweat chloride test (if cystic fibrosis suspected — rare in Indian adults but possible).
Specialist initiation: ⚠️ Recommended — bronchiectasis management (including acute exacerbation) should ideally involve a pulmonologist. For a first or straightforward exacerbation in a patient with established bronchiectasis and a known susceptible pathogen, a general physician can initiate amoxicillin. But: (a) sputum culture should be sent before starting antibiotics; (b) the patient should have a pulmonologist involved in their long-term care; © escalation to specialist input if treatment failure, Pseudomonas isolation, frequent exacerbations, or diagnostic uncertainty.
Indian guideline source: API Textbook of Medicine (current edition) — chapter on Bronchiectasis; BTS Bronchiectasis Guideline (2019, adapted for Indian practice); ERS Bronchiectasis Guideline (2017); Indian Chest Society clinical practice statements. ℹ️ No specific ICMR guideline on bronchiectasis management exists — practice is primarily guided by API Textbook and adapted international guidelines.
Key disease-specific safety warning: ⚠️ Always consider TB reactivation in any Indian patient with bronchiectasis (especially post-TB bronchiectasis) presenting with “acute exacerbation.” Sputum AFB/GeneXpert should be sent with EVERY exacerbation in patients with post-TB bronchiectasis. Treating a TB relapse with amoxicillin alone will result in: (a) partial symptomatic improvement (amoxicillin has weak anti-mycobacterial activity + treats secondary bacterial infection); (b) delayed TB diagnosis; © ongoing TB transmission; (d) potential development of drug-resistant TB. ⚠️ This is the same concern as in CAP but is MAGNIFIED in bronchiectasis because the underlying structural lung damage from prior TB is the most common cause of bronchiectasis in India.
Common dose adjustment scenarios:
- Renal impairment: Standard adjustments (see RENAL ADJUSTMENT — reduce dose/extend interval if eGFR <30).
- Elderly patients with bronchiectasis: Common scenario in India. Standard dosing unless renal impairment requires adjustment. Monitor for GI side effects (diarrhoea in elderly can be debilitating).
- Patients on long-term macrolide prophylaxis (azithromycin 250 mg 3 times/week): Many bronchiectasis patients with frequent exacerbations (≥3/year) are placed on long-term low-dose azithromycin for exacerbation reduction. When such patients develop an acute exacerbation, do NOT use azithromycin as the treatment antibiotic (already receiving it as prophylaxis → likely reduced efficacy). Use amoxicillin (or amoxicillin-clavulanate) for the acute exacerbation. Continue the azithromycin prophylaxis during the acute treatment course (some centres pause it; practice varies).

6. ACTINOMYCOSIS — ORAL STEP-DOWN THERAPY

OFF-LABEL

Phase	Route	Dose	Frequency	Duration	Notes
Step-down (after initial IV penicillin G)	Oral	500 mg–1 g per dose	TDS	6–12 months total (prolonged oral therapy essential to prevent relapse)	After 2–6 weeks of IV benzylpenicillin, switch to oral amoxicillin for the remainder of the course. Actinomyces israelii is universally susceptible to penicillins.

Evidence basis: Level of evidence: Weak (case series, expert consensus; standard infectious disease practice).

7. CHLAMYDIAL INFECTION IN PREGNANCY — ALTERNATIVE

OFF-LABEL but accepted standard practice in India

Route	Dose	Frequency	Duration	Notes
Oral	500 mg per dose	TDS	7 days	Alternative to azithromycin 1 g single dose (first-line for chlamydia in pregnancy). Amoxicillin is effective against Chlamydia trachomatis at this dose. Used when azithromycin is unavailable or not tolerated. ⚠️ Doxycycline (standard treatment for chlamydia in non-pregnant patients) is ⛔ CONTRAINDICATED in pregnancy.

Evidence basis: Level of evidence: Moderate (CDC STI Treatment Guidelines list amoxicillin as alternative for chlamydia in pregnancy; adapted for Indian practice per NACO STI guidelines).

PAEDIATRIC DOSING (Specialist Only)

⛔ The “Specialist Only” heading is a template requirement. Amoxicillin is one of the most commonly prescribed paediatric antibiotics in India and does NOT require specialist initiation for most indications. PHC/CHC-level prescribing by paediatricians and general practitioners is appropriate for standard indications (pharyngitis, AOM, pneumonia, UTI). Specialist initiation is needed only for complex infections, neonatal dosing, and endocarditis prophylaxis.

General Notes:

Safety monitoring requirements specific to paediatric use:
- Penicillin allergy assessment is MANDATORY before every new prescription — ask the parent/caregiver specifically about previous reactions to amoxicillin, augmentin (co-amoxiclav), or any other antibiotic.
- ⚠️ Aminopenicillin rash in EBV infection: Children with infectious mononucleosis (EBV) who receive amoxicillin develop a characteristic widespread maculopapular rash in ~70–100% of cases. This is NOT an IgE-mediated allergy. Do NOT label the child as “penicillin-allergic” — document as “EBV-associated aminopenicillin rash — NOT allergic.” If pharyngitis in a child may be due to EBV (atypical features — significant hepatosplenomegaly, prominent fatigue, generalised lymphadenopathy, atypical lymphocytes on smear): consider monospot/EBV serology before prescribing amoxicillin.
- Monitor for GI side effects (diarrhoea — common; nappy/diaper rash in infants secondary to diarrhoea).
- ⚠️ Monitor adherence — especially for 10-day GAS pharyngitis courses. Parental counselling about course completion is critical in India where premature antibiotic discontinuation is extremely prevalent.
Minimum age:
- Amoxicillin can be used from birth (including preterm neonates) — see Neonatal Dosing below.
- The oral suspension (125 mg/5 mL and 250 mg/5 mL) and dispersible tablets allow accurate dosing for all paediatric ages.
Minimum weight: No strict minimum weight threshold — dosing is weight-based (mg/kg). Oral suspension and drops (100 mg/mL) allow accurate dosing for low-birth-weight and preterm infants.
Formulation suitability for children:
- Oral suspension / Dry syrup (125 mg/5 mL, 250 mg/5 mL): ✅ Excellent paediatric formulation. Widely available across India from multiple manufacturers. ✅ Palatability: Good to excellent — most Indian brands offer flavoured suspensions (strawberry, banana, orange, mango). Significantly better-tasting than phenoxymethylpenicillin, cloxacillin, or erythromycin suspensions. This is a major practical advantage for paediatric adherence. Measure with graduated oral syringe — NOT a household teaspoon.
- Dispersible tablets (DT — 125 mg, 250 mg, 500 mg): ✅ WHO-preferred paediatric formulation. Can be dispersed in 5–10 mL of clean water to form a palatable suspension. Stable in tropical conditions (no cold-chain needed, no reconstitution shelf-life limitation). Increasingly available through NHM/government supply and Jan Aushadhi stores. ℹ️ Practical advantage over dry syrup: DTs do not require reconstitution, have longer shelf life, and are easier to transport and store in hot Indian conditions. Recommended by WHO for use in resource-limited settings.
- Oral drops (100 mg/mL — paediatric concentrated drops): Suitable for infants where small volumes are needed. ⚠️ Concentration-verification is critical: 100 mg/mL (drops) ≠ 25 mg/mL (some syrup formulations). A 4-fold dosing error can occur if drops are confused with syrup. Always verify the concentration on the product label before calculating the dose volume.
- Capsules (250 mg, 500 mg): Suitable for children ≥6 years who can swallow capsules whole. Do NOT open capsules and mix with food (no stability data; unpleasant taste of granules).
- Tablets (250 mg, 500 mg, 875 mg): Suitable for older children/adolescents who can swallow tablets. Film-coated — swallow whole.
Palatability: ✅ Amoxicillin suspension is one of the best-tolerated oral antibiotic formulations in paediatric practice in India. This is a significant advantage over: phenoxymethylpenicillin (bitter), cloxacillin (bitter), erythromycin (bitter/metallic), and clarithromycin (bitter). The good palatability contributes to better adherence and is one reason amoxicillin has largely replaced penicillin V for paediatric GAS pharyngitis in India.
Age-specific pharmacokinetic differences:
- Neonates (<28 days): Half-life prolonged (3–4 hours in term; 6–8 hours in preterm) due to immature renal tubular secretion. Requires extended dosing intervals (every 8–12 hours instead of every 8 hours). See Neonatal Dosing below.
- Infants (1–6 months): Half-life approximately 2–3 hours. Standard weight-based dosing with every-8-hour frequency applies. Higher doses (up to 90 mg/kg/day) may be needed for AOM and pneumonia with suspected intermediate-resistant pneumococcus.
- Children (>6 months to 12 years): Half-life approximately 1–1.5 hours (adult values). Clearance per kg is similar to adults. Weight-based dosing applies.
- Adolescents (≥12 years or ≥40 kg): Transition to adult dosing (fixed-dose).

Dosing method: Weight-based (mg/kg/day divided into doses) — mandatory for all paediatric dosing. Fixed adult doses apply only for children ≥40 kg.

Adolescent transition: Children ≥12 years AND ≥40 kg may use adult fixed-dose regimens (e.g., 500 mg TDS, 875 mg BD, 1 g BD). For children 12–18 years weighing <40 kg, continue weight-based dosing with adult maximum ceiling.

Neonatal Dosing (<28 days of life)

⛔ Neonatal use — NICU / neonatal unit supervision recommended for serious infections. However, amoxicillin is safe in neonates and is widely used in Indian neonatal practice.

ℹ️ Context for neonatal amoxicillin use in India: Oral amoxicillin is used in neonates primarily for:

Step-down from IV ampicillin after initial treatment of neonatal sepsis (when clinically improving and oral feeds are established)
Outpatient treatment of possible serious bacterial infection (PSBI) in young infants when referral is not feasible — per WHO Simplified Antibiotic Regimen and MoHFW F-IMNCI guidelines (see below)
UTI treatment in neonates (after initial parenteral therapy, for susceptible organisms)

⚠️ For confirmed or suspected neonatal sepsis and meningitis: the standard first-line regimen is IV ampicillin (or IV benzylpenicillin) + gentamicin — NOT oral amoxicillin. See benzylpenicillin and ampicillin monographs.

Neonatal dosing table — Oral Amoxicillin:

Gestational/Postnatal Age	Dose	Frequency	Max Daily Dose	Notes
Preterm <32 weeks, postnatal age 0–7 days	25 mg/kg/dose	Every 12 hours (BD)	50 mg/kg/day	⚠️ Prolonged half-life (6–8 hours). Immature renal clearance. Use oral route ONLY when feeds are established and GI absorption is reliable. For serious infections: use IV ampicillin, not oral amoxicillin.
Preterm <32 weeks, postnatal age 8–28 days	25 mg/kg/dose	Every 8 hours (TDS)	75 mg/kg/day	Renal maturation allows TDS frequency.
Preterm 32–36 weeks, postnatal age 0–7 days	25 mg/kg/dose	Every 8–12 hours (TDS or BD)	50–75 mg/kg/day
Preterm 32–36 weeks, postnatal age 8–28 days	25 mg/kg/dose	Every 8 hours (TDS)	75 mg/kg/day
Term ≥37 weeks, postnatal age 0–7 days	25–30 mg/kg/dose	Every 8 hours (TDS)	75–90 mg/kg/day
Term ≥37 weeks, postnatal age 8–28 days	25–30 mg/kg/dose	Every 8 hours (TDS)	75–90 mg/kg/day	Approaching standard infant dosing frequency.

WHO/MoHFW Simplified Antibiotic Regimen for PSBI in Young Infants (0–59 days) When Referral is NOT Feasible:

ℹ️ This is a critically important protocol in Indian public health. Under the F-IMNCI programme and WHO Community-Based Management of PSBI guidelines, when a young infant (0–59 days) with possible serious bacterial infection (PSBI) cannot be referred to a hospital (family refusal, geographical barriers, no transport), the following simplified outpatient regimen is used:

Component	Dose	Route	Frequency	Duration
Amoxicillin	50 mg/kg/dose	Oral	BD	7 days
+ Gentamicin	5 mg/kg/dose (birth weight ≥2 kg) or 4 mg/kg (<2 kg)	IM	OD	2 days (Days 1 and 2 only)

ℹ️ This regimen is used by ASHAs, ANMs, and PHC medical officers in Indian community settings. The 2-day IM gentamicin provides rapid bactericidal cover while the oral amoxicillin provides sustained antibiotic exposure for 7 days. This protocol has been validated in the AFRINEST and other landmark RCTs and is endorsed by WHO and MoHFW for settings where hospital referral is genuinely not feasible.

⚠️ This regimen is NOT a substitute for hospital-based IV antibiotic therapy when referral IS feasible. If the infant can be referred, standard IV ampicillin + gentamicin is the preferred regimen.

Indian source: MoHFW F-IMNCI Guidelines; WHO Recommendations on Newborn Health (updated 2017); National Health Mission (NHM) HBNC+ programme.

Primary Indications — Paediatric (Approved / Standard in India)

1. GROUP A STREPTOCOCCAL (GAS) PHARYNGITIS / TONSILLITIS — Treatment (Paediatric — Primary RF Prevention)

Weight-based dosing — Children ≥1 month to <12 years (or <40 kg):

Dose	Frequency	Duration	Maximum Daily Dose	Formulation	Notes
25 mg/kg/dose	BD (every 12 hours) — PREFERRED for compliance	10 days	Max 500 mg per dose; Max 1 g per day (adult ceiling)	Oral suspension (125 mg/5 mL or 250 mg/5 mL) OR dispersible tablets (125 mg or 250 mg)	ℹ️ IAP 2017 Guidelines, WHO, and AHA endorse BD dosing with amoxicillin for GAS pharyngitis in children. Total daily dose ~50 mg/kg/day — divided BD. This is the PREFERRED regimen in current Indian paediatric practice.
13–17 mg/kg/dose (alternative)	TDS (every 8 hours)	10 days	Max 500 mg per dose; Max 1 g per day	Same	Traditional TDS regimen. Total daily dose ~40–50 mg/kg/day. Equally effective but inferior adherence compared to BD.

ℹ️ Simplified dosing (IAP-endorsed): For practical outpatient prescribing, amoxicillin 50 mg/kg/day divided BD (or 40 mg/kg/day divided TDS) × 10 days is the standard. Most IAP and Indian paediatric guidelines present this as a simple weight-band table rather than exact mg/kg calculations:

Weight Band	Dose (BD regimen)	Volume (125 mg/5 mL suspension)	Volume (250 mg/5 mL suspension)
5–9 kg (~3 months–1 year)	125 mg BD	5 mL BD	2.5 mL BD
10–19 kg (~1–5 years)	250 mg BD	10 mL BD	5 mL BD
20–39 kg (~6–11 years)	500 mg BD	— (use tablets/capsules or 250 mg/5 mL: 10 mL BD)	10 mL BD or 500 mg capsule BD
≥40 kg (≥~12 years)	500 mg BD (adult dose)	Use capsules/tablets	Use capsules/tablets

Mandatory Clinical Notes (Paediatric-specific):

When to prefer amoxicillin over penicillin V for GAS pharyngitis in children: ✅ Amoxicillin is preferred in most Indian paediatric settings because: (a) significantly better palatability of suspension (children accept it far more readily); (b) food-independent absorption (no need for empty-stomach dosing — much simpler for families); © simpler BD dosing; (d) wider availability in Indian pharmacies.
When NOT to use:
- ⛔ Penicillin allergy — use azithromycin (12 mg/kg/day OD × 5 days, max 500 mg/day) or clarithromycin (15 mg/kg/day divided BD × 10 days).
- ⚠️ Suspected mononucleosis (EBV): Do NOT prescribe amoxicillin until EBV is excluded (see General Notes above). If EBV is suspected: no antibiotic needed (viral infection); if bacterial superinfection of pharynx is suspected in EBV-positive patient, use azithromycin or cephalexin (non-aminopenicillin).
- ⚠️ Do NOT prescribe for viral pharyngitis. In children <3 years, GAS pharyngitis is uncommon — most pharyngitis in this age group is viral. Antibiotics are rarely indicated for pharyngitis in children <3 years unless there is strong clinical evidence of GAS (household contact with confirmed GAS, scarlet fever-like rash, strawberry tongue).
- ⚠️ Do NOT use shortened courses (<10 days) — incomplete RF prevention.
NLEM status: ✅ NLEM-listed (amoxicillin capsules, suspension, and dispersible tablets).
Time to response: Symptom improvement within 24–48 hours.
Treatment failure: Persistent symptoms after 48–72 hours despite confirmed adherence. Options: (a) repeat 10-day course with amoxicillin (compliance may have been the issue); (b) switch to amoxicillin-clavulanate (875/125 mg equivalent weight-based dose) × 10 days; © clindamycin 20 mg/kg/day divided TDS × 10 days; (d) single IM benzathine penicillin (guarantees eradication).
Specialist initiation: Not required. PHC/CHC-level prescribing is appropriate.
Indian source: IAP Guidelines on Acute Pharyngitis and RF Prevention (2017); IAP Textbook of Pediatrics (current edition); WHO RF Prevention Guidelines.
Safety warning: ⚠️ Complete the full 10-day course — counsel parents emphatically. Use a calendar/sticker chart to engage the child. Consider single-dose IM benzathine penicillin if adherence is genuinely doubtful.

2. ACUTE OTITIS MEDIA (AOM) — Paediatric

Clinical context: Amoxicillin is the first-line antibiotic for paediatric AOM (IAP guidelines, AAP/AAFP guidelines adapted for India). ⚠️ “Watchful waiting” (delayed prescription/observation without antibiotics for 48–72 hours) is acceptable for mild AOM in children ≥6 months without risk factors (unilateral AOM, no otorrhoea, non-severe symptoms, no recent antibiotics, no craniofacial abnormalities). If symptoms persist or worsen after 48–72 hours of observation, start antibiotics. ⚠️ In Indian practice, most paediatricians prescribe antibiotics immediately for all AOM — watchful waiting is less commonly practiced, partly due to follow-up reliability concerns.

Weight-based dosing — Children ≥6 months to <12 years:

Clinical Scenario	Dose	Frequency	Duration	Max Daily Dose	Notes
Standard-dose amoxicillin (uncomplicated AOM, no risk factors for resistance)	40–45 mg/kg/day divided into doses	TDS (every 8 hours) OR BD (every 12 hours)	5 days (children ≥2 years with mild AOM); 10 days (children <2 years, severe AOM, recurrent AOM, bilateral AOM)	Max 500 mg per dose (TDS) or 750 mg per dose (BD)	Standard initial therapy.
High-dose amoxicillin (risk factors for penicillin-intermediate pneumococcus)	⚠️ 80–90 mg/kg/day divided into doses	BD (every 12 hours) — preferred for high-dose regimen (larger individual dose, fewer doses/day)	10 days	Max 1 g per dose; Max 2 g per day	⚠️ High-dose is recommended for: (a) children <2 years; (b) daycare attendees; © antibiotic use within the past 30 days; (d) bilateral AOM; (e) AOM with otorrhoea; (f) regions with high pneumococcal resistance. IAP and AAP/AAFP guidelines recommend high-dose amoxicillin as first-line for most paediatric AOM in India — because multiple risk factors are commonly present in Indian children (crowded living conditions, frequent antibiotic exposure).

ℹ️ Practical high-dose amoxicillin calculation example:

A 15 kg child with bilateral AOM: High-dose amoxicillin 90 mg/kg/day.

- Total daily dose = 15 × 90 = 1,350 mg/day
- Divided BD = 675 mg per dose (~700 mg per dose — round to nearest practical volume)
- Using 250 mg/5 mL suspension: 700 mg = 14 mL per dose → 14 mL BD
- ℹ️ This is a LARGE volume for a child — may need to divide into 2 aliquots or consider using dispersible tablets if the child can manage them.

Mandatory Clinical Notes (Paediatric-specific):

When to prefer: Amoxicillin is first-line for AOM. High-dose amoxicillin (80–90 mg/kg/day) is increasingly used as the DEFAULT dose for paediatric AOM in India rather than standard dose.
When NOT to use:
- AOM treatment failure after 48–72 hours of amoxicillin → switch to amoxicillin-clavulanate (high dose: 90 mg/kg/day of amoxicillin component, divided BD) × 10 days, OR cefuroxime axetil (30 mg/kg/day divided BD × 10 days).
- ⚠️ Penicillin allergy: Non-anaphylactic: cefuroxime axetil or cefdinir. Anaphylactic: azithromycin 10 mg/kg Day 1, then 5 mg/kg Days 2–5 (total 5 days), OR clindamycin 30 mg/kg/day divided TDS × 10 days.
- AOM with mastoiditis → hospitalise + IV antibiotics + ENT consultation.
NLEM status: ✅ NLEM-listed.
Time to response: Improvement in ear pain and fever within 48–72 hours.
Treatment failure: Persistent or worsening symptoms at 48–72 hours → switch antibiotic (see above). If recurrent AOM (≥3 episodes in 6 months or ≥4 in 12 months) → ENT referral for consideration of tympanostomy tubes.
Indian source: IAP Guidelines on AOM Management; AAP/AAFP AOM Guideline (2013, adapted for India).
Safety warning: ⚠️ Diarrhoea is the most common adverse effect of high-dose amoxicillin in children (10–20%). Counsel parents: mild diarrhoea is expected and usually self-limiting. Maintain hydration. If diarrhoea is severe, bloody, or persistent: consider C. difficile (rare in children but possible) and review antibiotic. ⚠️ Nappy/diaper rash may worsen due to diarrhoea — barrier cream (zinc oxide) prophylactically during the antibiotic course.

3. COMMUNITY-ACQUIRED PNEUMONIA — Paediatric (Mild, Outpatient)

Weight-based dosing — Children ≥2 months to <12 years:

Severity	Dose	Frequency	Duration	Max Daily Dose	Notes
Non-severe pneumonia (no danger signs — tachypnoea only, able to feed, no chest indrawing)	40–50 mg/kg/day divided into doses	TDS (every 8 hours) OR BD	5 days (per WHO and IAP — shorter courses are effective for non-severe CAP in children)	Max 500 mg per dose	ℹ️ WHO and IAP recommend 5-day oral amoxicillin for non-severe childhood pneumonia managed at home. This has been validated in multiple RCTs (including the ISCAP study — Indian multicentre trial). ⚠️ The 5-day course applies ONLY to non-severe pneumonia without danger signs.
High-dose (for suspected penicillin-intermediate pneumococcus or slow response)	80–90 mg/kg/day divided into doses	BD or TDS	7–10 days	Max 1 g per dose	Use when standard dose is inadequate or risk factors for pneumococcal resistance are present.

⚠️ IAP Danger Signs in childhood pneumonia requiring HOSPITALISATION (NOT suitable for oral outpatient amoxicillin): (a) inability to feed/drink; (b) persistent vomiting; © convulsions; (d) lethargy/unconsciousness; (e) stridor in a calm child; (f) severe malnutrition; (g) SpO₂ <92% (or <90% at altitude). If any danger sign is present → hospitalise → IV antibiotics (ampicillin + gentamicin, or ceftriaxone).

⚠️ Under-5 pneumonia and mortality in India: Pneumonia remains the leading infectious cause of death in children under 5 in India. Timely recognition, appropriate antibiotic initiation, and recognition of danger signs are critical. The IMNCI programme trains frontline health workers to identify pneumonia (respiratory rate counting) and initiate oral amoxicillin at the community level.

Indian source: IAP Guidelines on Pneumonia Management; WHO Pocket Book of Hospital Care for Children (Indian adaptation); MoHFW IMNCI/F-IMNCI Guidelines; ISCAP Trial (Indian multicentre RCT validating 3-day vs 5-day amoxicillin for non-severe pneumonia).

4. URINARY TRACT INFECTIONS — Paediatric (Directed Therapy)

Weight-based dosing — Children ≥1 month to <12 years:

Condition	Dose	Frequency	Duration	Notes
Lower UTI (cystitis) — confirmed susceptible	25–50 mg/kg/day divided into doses	TDS	3–5 days	Culture-guided ONLY. Not for empirical use (same high E. coli resistance rates as in adults).
Upper UTI (pyelonephritis) — step-down after IV therapy, confirmed susceptible	40–50 mg/kg/day divided into doses	TDS	Total 10–14 days (including initial IV phase)	Step-down from IV ampicillin or ceftriaxone when clinically improving and culture confirms susceptibility.

Indian source: IAP Guidelines on UTI Management in Children; Indian Pediatric Nephrology Group (IPNG) recommendations.

5. DENTAL PROPHYLAXIS FOR ENDOCARDITIS — Paediatric

Weight-based dosing — Children <40 kg:

Route	Dose	Timing	Notes
Oral	50 mg/kg as a SINGLE DOSE	30–60 minutes before dental procedure	Max 2 g per dose (adult ceiling). For penicillin-allergic children: azithromycin 15 mg/kg (max 500 mg) × 1 dose OR cephalexin 50 mg/kg (max 2 g) × 1 dose (if non-anaphylactic allergy) OR clindamycin 20 mg/kg (max 600 mg) × 1 dose (if anaphylactic allergy).

6. HELICOBACTER PYLORI ERADICATION — Paediatric

Weight-based dosing — Children ≥6 years (when H. pylori eradication is indicated):

Regimen	Amoxicillin Dose	Other Components	Duration	Notes
Standard Triple Therapy	50 mg/kg/day divided BD (max 1 g per dose)	+ PPI (1 mg/kg/dose BD, max standard adult PPI dose) + Clarithromycin 15 mg/kg/day divided BD (max 500 mg per dose)	14 days	ℹ️ H. pylori eradication in children is less commonly indicated than in adults — restricted to confirmed peptic ulcer disease, refractory iron deficiency anaemia with H. pylori, and MALT lymphoma (very rare in children). IAP/ESPGHAN guidelines recommend confirming H. pylori infection before treatment in children.

Secondary Indications — Paediatric (Off-label)

1. WHO SIMPLIFIED ANTIBIOTIC REGIMEN FOR PSBI IN YOUNG INFANTS (0–59 Days)

OFF-LABEL but accepted standard practice in India (endorsed by MoHFW, WHO, NHM)

See Neonatal Dosing section above for full details. Amoxicillin 50 mg/kg/dose oral BD × 7 days + Gentamicin IM OD × 2 days. Used when hospital referral for a young infant with PSBI is genuinely not feasible.

Evidence basis: Level of evidence: Strong (paediatric RCTs — AFRINEST, SATT, and other multicentre trials; WHO recommendation; MoHFW F-IMNCI endorsement).

2. LYME DISEASE — Paediatric (Early)

OFF-LABEL

Dose	Frequency	Duration	Notes
50 mg/kg/day divided TDS (max 500 mg per dose)	TDS	14–21 days	Alternative to doxycycline (which is avoided in children <8 years due to tooth staining). Amoxicillin is the preferred agent for early Lyme disease in young children. Lyme disease is rare in India.

Evidence basis: Level of evidence: Moderate (adult RCTs with paediatric PK extrapolation; IDSA/AAN guidelines).

3. POST-SPLENECTOMY / HYPOSPLENIC STATES — Antibiotic Prophylaxis (Paediatric)

OFF-LABEL but accepted standard practice in India

ℹ️ Some protocols use amoxicillin instead of phenoxymethylpenicillin for post-splenectomy prophylaxis in children — offering better bioavailability, food independence, and palatability.

Age	Dose	Frequency	Duration	Notes
<5 years	125 mg per dose	BD	Lifelong or until adulthood (specialist-determined)	Alternative to phenoxymethylpenicillin 125 mg BD. Concurrent vaccination (PCV13, PPSV23, Hib, meningococcal) is MANDATORY.
≥5 years	250 mg per dose	BD	Lifelong or until adulthood	Alternative to phenoxymethylpenicillin 250 mg BD.

Evidence basis: Level of evidence: Moderate (endorsed by several international haematology guidelines as equivalent alternative to penicillin V; adapted for Indian practice at AIIMS, CMC Vellore haematology departments).

4. SICKLE CELL DISEASE — Pneumococcal Prophylaxis (Paediatric) — Alternative to Penicillin V

OFF-LABEL but accepted standard practice at some Indian centres

ℹ️ Some Indian haematology centres use amoxicillin instead of phenoxymethylpenicillin for SCD prophylaxis — equivalent efficacy with better palatability and no food restriction.

Age	Dose	Frequency	Duration	Notes
2 months–3 years	10–20 mg/kg/dose	BD	Lifelong (in most Indian protocols)	Concurrent vaccination MANDATORY.
3–5 years	125–250 mg per dose	BD	Lifelong
≥5 years	250 mg per dose	BD	Lifelong

Evidence basis: Level of evidence: Weak (not validated in the original PROPS trial, which used penicillin V; accepted as equivalent based on pharmacological equivalence and clinical experience; practice-based at some Indian SCD centres).

MISSED DOSE / DELAYED DOSE GUIDANCE

Context-specific guidance by dosing frequency and clinical use:

1. BD Dosing (Every 12 Hours — GAS Pharyngitis, AOM, RF Prophylaxis Alternative):

Scenario	Guidance
Dose delayed by <6 hours	Take the dose as soon as remembered. Resume regular schedule.
Dose delayed by >6 hours (but next dose not imminent)	Take the dose. Adjust subsequent dose timing to maintain approximately 12-hour spacing.
Dose missed entirely (next scheduled dose is within 4 hours)	Skip the missed dose. Take the next dose at the scheduled time.
⛔ Never double up	Do NOT take two doses at once.

2. TDS Dosing (Every 8 Hours — Pneumonia, UTI, Sinusitis, Standard Infections):

Scenario	Guidance
Dose delayed by <4 hours	Take the dose as soon as remembered. Resume regular schedule.
Dose delayed by >4 hours	Take the dose. Adjust subsequent doses to maintain roughly equal spacing for the rest of the day.
Dose missed entirely (next dose imminent)	Skip. Take next scheduled dose on time.
⛔ Never double up	Do NOT take two doses at once.

3. GAS Pharyngitis (10-Day Course) — Missed Dose Impact:

Scenario	Guidance
1–2 isolated missed doses during the 10-day course	Continue the course. Extend by 1 day to compensate for the missed day, ensuring a full 10 days of active treatment.
≥3 consecutive doses missed (>24 hours without medication)	Contact the prescriber. Depending on the number of days already completed and the number of days missed, the course may need to be restarted from the beginning (especially if <5 days had been completed before the interruption). If >7 days of the course were completed before the interruption, completing the remaining days (extended by 1 day) is usually acceptable.

4. H. pylori Eradication (14-Day Triple/Quadruple Therapy) — Missed Dose Impact:

Scenario	Guidance
1–2 isolated missed doses	Continue the regimen. The 14-day course has some built-in redundancy. Missing occasional doses is unlikely to cause treatment failure if the majority of doses are taken.
≥3 consecutive days missed	⚠️ The likelihood of eradication failure increases significantly. Contact the prescriber. The course may need to be restarted with a DIFFERENT regimen (to account for potential selection of resistant organisms during the incomplete course).

5. Prolonged Non-Adherence / Drug Holiday Guidance:

Amoxicillin does NOT carry risk of rebound effects, withdrawal syndrome, or immunogenicity upon discontinuation or resumption.

No withdrawal syndrome — can be stopped and restarted at any time.
No rebound phenomenon — stopping simply allows the infection to persist or recur if treatment was incomplete.
No re-titration needed — resume at the previous dose.
Not a biologic — no immunogenicity concern.

For prophylaxis (post-splenectomy, SCD): Same guidance as phenoxymethylpenicillin — resume immediately at the previous dose. Counsel about the risk of OPSI during the unprotected period. Ensure vaccinations are current.

For incomplete treatment courses: If a treatment course (pharyngitis, pneumonia, UTI) was interrupted for >48 hours: reassess clinically. If symptoms have resolved, completing the remaining course is usually adequate. If symptoms have recurred, restart the full course (or consider a different antibiotic if treatment failure is suspected).

RECONSTITUTION / ADMINISTRATION QUICK REFERENCE (For Nurses & Clinical Staff)

Oral Suspension / Dry Syrup — Reconstitution

Parameter	Details
Supplied as	Dry powder/granules in a bottle. Available as 125 mg/5 mL, 250 mg/5 mL, or 400 mg/5 mL (some brands) after reconstitution. Bottle sizes: 30 mL, 60 mL, 90 mL, 100 mL depending on manufacturer.
Diluent	Freshly boiled and cooled water (or clean drinking water). Follow manufacturer instructions for exact volume.
Reconstitution steps	(1) Tap/shake the bottle to loosen powder. (2) Add approximately half the required volume of water. (3) Shake vigorously until all powder is uniformly suspended. (4) Add remaining water to the mark indicated on the bottle. (5) Shake again thoroughly. (6) Label with date of reconstitution and discard date.
Final appearance	Opaque suspension — colour varies by brand and flavouring (white, pink, yellow, orange). ⚠️ If clear instead of opaque → powder was not properly suspended. Add water and reshake.

Stability After Reconstitution:

Condition	Stability
Room temperature (25°C)	⚠️ Use within 7 days. In Indian conditions where ambient temperature regularly exceeds 30°C: use within 5 days if not refrigerated.
Refrigerated (2–8°C)	✅ Stable for 14 days. ℹ️ Refrigeration is strongly recommended in India, especially during March–October (summer and monsoon months).
Light protection	Not specifically required. Store in original bottle (usually opaque plastic).

ℹ️ Indian climate note: Same practical guidance as for phenoxymethylpenicillin suspension — if no refrigerator is available: store in the coolest part of the house (not kitchen, not near windows), wrap in damp cloth inside an earthen pot (matka), and use within 5 days. If the full course requires >5 days of suspension (e.g., 10-day pharyngitis course at BD dosing), the family will need either: (a) refrigeration; (b) a second bottle reconstituted fresh at day 5; or © dispersible tablets (which do NOT require reconstitution and have no stability limitations — recommended by WHO for resource-limited tropical settings).

💡 Dispersible tablets (DT) — the practical solution for India’s heat: Unlike dry syrups, amoxicillin DTs are stable at room temperature for their full shelf life (typically 2–3 years). Each tablet is individually dosed (125 mg or 250 mg). Simply disperse in 5–10 mL of clean water immediately before administration. No reconstitution, no refrigeration, no shelf-life limitation after “opening.” This makes DTs the ideal formulation for: (a) rural and remote India without reliable refrigeration; (b) ambulatory patients; © community health worker-administered doses (IMNCI/F-IMNCI programmes).

Oral Capsules and Tablets — Administration

Parameter	Details
Swallow whole	Capsules: swallow whole with water. Do NOT open and sprinkle (no stability data; granules have unpleasant taste). Tablets (film-coated): swallow whole.
Crush/split allowed?	Film-coated tablets: NOT recommended to crush (no stability data; may alter absorption characteristics). If the patient cannot swallow tablets, use oral suspension or dispersible tablets instead. Dispersible tablets (DT): ✅ Designed to be dispersed in water — this IS the intended route of administration. Do NOT swallow whole if the child cannot swallow tablets.
Chewable tablets	Some manufacturers market chewable amoxicillin tablets (125 mg, 250 mg). These should be thoroughly chewed before swallowing. Suitable for children ≥4 years who can chew effectively. Verify that the specific product IS a chewable formulation before advising the patient to chew.
Enteral tube (NG/NJ tube)	✅ Compatible. Options: (a) Oral suspension — administer directly via the tube. Flush with 10–20 mL water before and after. (b) Dispersible tablet — disperse in 10–20 mL water, administer via tube, flush thoroughly. © Capsule contents — opened and mixed with 10–20 mL water (off-label, no stability data, but commonly done in ICU practice).
Timing relative to meals	✅ May be taken with or without food. Food does NOT significantly reduce absorption (unlike phenoxymethylpenicillin or ampicillin). Taking with food may reduce GI side effects (nausea).

Injectable Amoxicillin — Reconstitution (Limited Availability in India)

ℹ️ Single-ingredient amoxicillin injection is rarely available in Indian hospitals. When parenteral aminopenicillin is needed, IV ampicillin (widely available) or IV amoxicillin-clavulanate (widely available) are the practical options. The following information is provided for completeness, applicable if amoxicillin sodium injection IS available:

Parameter	Details
Supplied as	Amoxicillin sodium powder for injection: 250 mg, 500 mg, 1 g vials.
Reconstitution diluent	Sterile Water for Injection (SWFI) — preferred.
Reconstitution volume	250 mg vial: add 5 mL SWFI. 500 mg vial: add 10 mL SWFI. 1 g vial: add 20 mL SWFI.
Further dilution for IV infusion	Dilute reconstituted solution in 50–100 mL of 0.9% NaCl (NS). ⚠️ Less stable in D5W — use NS preferentially.
Rate of IV administration	IV bolus: Administer over 3–5 minutes. IV infusion: Over 15–30 minutes.
Stability after reconstitution	Use within 1 hour at room temperature (amoxicillin sodium solutions are LESS stable than ampicillin). Refrigerated: use within 6–8 hours. ⚠️ Amoxicillin injection is notably less stable in solution than many other antibiotics — prepare freshly for each dose.
Incompatibilities	⛔ Do NOT mix with aminoglycosides (gentamicin, amikacin) in the same line/syringe (physical inactivation of aminoglycoside). Flush with ≥20 mL NS between drugs. ⛔ Do NOT mix with blood products or lipid emulsions.

Multi-Dose Container Handling (Oral Suspension Bottle):

Parameter	Details
In-use shelf life	7 days at room temperature; 14 days refrigerated. Label bottle with reconstitution date and discard date.
Shake before use	⚠️ SHAKE WELL before every dose. The drug settles as a sediment when standing. Inadequate shaking → inconsistent dosing (initial doses too low, later doses too high). Counsel parents to shake the bottle vigorously for 10–15 seconds before each dose.
Measuring device	Use ONLY the graduated syringe or dosing cup provided with the product. If none is provided, use a pharmacy-grade oral syringe (available at most Indian pharmacies for ₹5–10). ⛔ Do NOT use a household teaspoon — inaccurate (delivers 3–7 mL instead of 5 mL).
Contamination prevention	Do NOT insert spoons, fingers, or the child’s mouth directly into the bottle. Pour or draw out the dose with a clean syringe/cup. Keep cap tightly closed.

Cold-Chain Drug Guidance:

Not a cold-chain drug. Powder (before reconstitution) is stored at room temperature (below 30°C). Reconstituted suspension benefits from refrigeration (14-day stability vs 7-day at room temperature) but refrigeration is NOT mandatory if the suspension is used within 5–7 days. Dispersible tablets require NO refrigeration at any stage.

Storage Summary:

Formulation	Before Opening/Reconstitution	After Opening/Reconstitution
Capsules/Tablets (blister/strip)	Room temperature, <30°C, protect from moisture.	Use before expiry date. No in-use stability concern.
Dispersible tablets (DT — blister/strip)	Room temperature, <30°C, protect from moisture.	Disperse in water immediately before use. Discard unused dispersed suspension.
Dry syrup (unreconstituted bottle)	Room temperature, <30°C, protect from moisture. Do NOT reconstitute in advance.	—
Oral suspension (after reconstitution)	—	Refrigerate (2–8°C): use within 14 days. Room temp (<30°C): use within 7 days (5 days if ambient >30°C). Shake well before each use.
Injection (powder vial — if available)	Room temperature, <25°C.	Use within 1 hour of reconstitution at room temp; within 6–8 hours if refrigerated.

RENAL ADJUSTMENT

eGFR formula specification: Dose adjustment recommendations are based on general pharmacokinetic principles and published guidance from multiple sources. Either CKD-EPI eGFR or Cockcroft-Gault CrCl can be used for clinical decision-making. The original pharmacokinetic studies used Cockcroft-Gault CrCl.

Key pharmacokinetic consideration: Approximately 60–70% of amoxicillin is excreted unchanged renally (via glomerular filtration + active tubular secretion via OAT1/OAT3). In severe renal impairment, the half-life increases from ~1–1.5 hours to 7–20 hours — significant drug accumulation occurs with standard dosing, increasing the risk of adverse effects (crystalluria at very high concentrations, neurotoxicity at extremely high levels — though neurotoxicity is much less common with oral amoxicillin than with high-dose IV benzylpenicillin).

eGFR (mL/min)	Dose Adjustment	Notes
>30	No adjustment required. Standard dosing applies for all indications.	The wide therapeutic index of amoxicillin means that modest accumulation at eGFR 30–60 is clinically insignificant.
15–30	⚠️ Standard dose (250–500 mg per dose) but extend interval to every 12 hours (BD) instead of every 8 hours (TDS). OR reduce dose to 250 mg TDS.	Half-life approximately 4–6 hours. Modest accumulation. Monitor for GI adverse effects (diarrhoea, nausea).
<15 (non-dialysis)	⚠️ Reduce to 250–500 mg every 12–24 hours (one or two doses daily). Max 500 mg per day for standard indications. For high-dose indications (AOM, pneumonia): specialist guidance — consider alternative antibiotic or cautious use at reduced dose.	Half-life 7–20 hours. Significant accumulation. ⚠️ Risk of crystalluria (amoxicillin crystals in urine) at very high urinary concentrations — maintain adequate hydration.
Haemodialysis	✅ Amoxicillin IS removed by haemodialysis. Standard dose: 250–500 mg pre-dialysis + give a supplemental dose of 250–500 mg AFTER each HD session. On non-dialysis days: 250–500 mg every 24 hours (based on residual renal function).	The large renal clearance fraction means HD removes a clinically significant proportion of the drug. Post-HD supplementation restores therapeutic levels.
Peritoneal dialysis	250–500 mg every 12–24 hours. Not significantly removed by PD (less efficient than HD for small molecules).	No specific post-PD supplemental dose.
CRRT	250–500 mg every 8–12 hours. CRRT provides continuous drug clearance — doses may need to be slightly higher than for intermittent HD but lower than for normal renal function.	Clinical judgement based on indication, severity, and CRRT settings. Specialist input recommended.

Augmented Renal Clearance (ARC): Amoxicillin clearance increases in ARC (CrCl >130 mL/min — common in young ICU patients with sepsis, trauma, burns). However, since amoxicillin is primarily an oral drug with limited ICU use (IV ampicillin or IV amoxicillin-clavulanate are used instead), ARC dose adjustments for amoxicillin are rarely relevant in practice. If oral amoxicillin IS used in a patient with ARC (e.g., step-down therapy): standard high-dose regimens (1 g TDS) are adequate — the wide therapeutic index provides a safety margin.

HEPATIC ADJUSTMENT

Primary clearance pathway: Renal excretion accounts for 60–70% of amoxicillin elimination as unchanged drug. Hepatic metabolism contributes only ~10–30% (hydrolysis to inactive penicilloic acid). No CYP450 involvement.

Dose adjustment in hepatic impairment:

Child-Pugh Class	Adjustment	Notes
A (Mild)	No adjustment required.
B (Moderate)	No adjustment required.
C (Severe)	No adjustment required.	Even in severe cirrhosis, the primary elimination route (renal) is unaffected by hepatic impairment alone. If hepatorenal syndrome is present (concurrent renal impairment), adjust for the renal component — see RENAL ADJUSTMENT.

No formal hepatic dosing data exists — none is needed, as hepatic metabolism plays a minor role in amoxicillin clearance.

Active metabolite accumulation: Not applicable — no active metabolites.

Protein binding in hepatic impairment: Amoxicillin is only ~17–20% protein-bound. Even in severe hypoalbuminaemia (cirrhosis, nephrotic syndrome), the change in free drug fraction is negligible. No clinical significance.

Concurrent hepatotoxin note: Amoxicillin is NOT significantly hepatotoxic as a single agent. However, the combination of amoxicillin + clavulanic acid (co-amoxiclav) IS associated with cholestatic hepatitis (see amoxicillin-clavulanate monograph — separate drug). This adverse effect is attributed to the clavulanic acid component, NOT to amoxicillin itself. ℹ️ If a patient has a history of amoxicillin-clavulanate-induced hepatitis, they can safely receive amoxicillin alone (without clavulanic acid) — the hepatotoxic agent is clavulanate, not amoxicillin.

Amoxicillin can be safely co-administered with hepatotoxic drugs commonly used in Indian practice (rifampicin, isoniazid, pyrazinamide, methotrexate, valproate, antiretrovirals) without specific hepatotoxicity concerns. No additional LFT monitoring is required for the amoxicillin component.

CONTRAINDICATIONS

⛔ Absolute contraindications — the drug must NEVER be used in these situations:

Contraindication	Clinical Rationale
⛔ Known IgE-mediated (Type I) hypersensitivity to any penicillin	Risk of anaphylaxis — bronchospasm, laryngeal oedema, hypotension, cardiovascular collapse, death. Onset within minutes to 1 hour of administration. History of anaphylaxis, angioedema, or urticaria within 1 hour of ANY penicillin (benzylpenicillin, phenoxymethylpenicillin, ampicillin, cloxacillin, piperacillin, amoxicillin, amoxicillin-clavulanate) constitutes an absolute contraindication. ℹ️ Amoxicillin shares the identical core beta-lactam + thiazolidine ring with all penicillins — cross-reactivity within the penicillin class is effectively 100%. A patient allergic to ANY penicillin is allergic to ALL penicillins.
⛔ Known severe hypersensitivity to amoxicillin-clavulanate with confirmed amoxicillin as the causative component	If a patient has had a documented allergic reaction to amoxicillin-clavulanate and the reaction has been attributed to the amoxicillin component (IgE-mediated — urticaria, angioedema, anaphylaxis), amoxicillin alone is also contraindicated. ℹ️ However: If the reaction to co-amoxiclav was cholestatic hepatitis (a known adverse effect of the clavulanic acid component, NOT amoxicillin), then amoxicillin alone CAN be safely used — the hepatotoxicity is from clavulanate, not amoxicillin. This distinction is clinically important and often missed.
⛔ Infectious mononucleosis (EBV infection) — relative contraindication elevated to near-absolute	⚠️ Aminopenicillins (amoxicillin, ampicillin) cause a characteristic widespread maculopapular rash in ~70–100% of patients with infectious mononucleosis. While this is NOT an IgE-mediated allergic reaction (it is a virus-drug interaction involving polyclonal B-cell activation), the rash can be extensive, distressing, and may lead to the patient being permanently and incorrectly labelled as “penicillin-allergic” — with lifelong clinical consequences (exclusion from penicillins for RF prophylaxis, syphilis treatment, endocarditis treatment). ⛔ Do NOT prescribe amoxicillin to patients with confirmed or suspected infectious mononucleosis. If antibiotic therapy is needed for suspected bacterial superinfection in an EBV-positive patient, use a non-aminopenicillin (azithromycin, cephalexin, clindamycin). ℹ️ Listed here as a near-absolute contraindication rather than a caution because: (a) the rash incidence is extremely high (~70–100%); (b) the consequences of the rash (false allergy labelling) are clinically significant and lifelong; © there are readily available alternatives.

Allergy Cross-Reactivity — Beta-Lactam Antibiotics:

The cross-reactivity profile is identical to that described in the benzylpenicillin and phenoxymethylpenicillin monographs. A summary is provided:

Drug/Class	Cross-Reactivity with Amoxicillin	Approximate Rate	Nature	Clinical Action
All penicillins (benzylpenicillin, phenoxymethylpenicillin, ampicillin, cloxacillin, piperacillin, etc.)	⛔ YES — very high (~100%)	Complete — identical core structure	Structure-based (predictable)	⛔ ALL penicillins contraindicated if IgE-mediated allergy to any penicillin.
Cephalexin / Cefadroxil (first-generation cephalosporins with R1 side chain identical to amoxicillin)	⚠️ Moderate (~2–4%)	Higher than other cephalosporins — SPECIFIC cross-reactive pair with amoxicillin due to identical R1 side chain	Structure-based (R1 side chain)	⚠️ Avoid cephalexin and cefadroxil specifically in patients with confirmed amoxicillin allergy. Other first-generation cephalosporins (cefazolin — different R1 side chain) carry lower risk (~1–2%).
Other first-generation cephalosporins (cefazolin)	Low (~1–2%)	R1 side chain differs from amoxicillin	Structure-based	⚠️ Avoid in severe (anaphylactic) penicillin allergy. May use with caution (first dose under observation) in non-severe allergy.
Second–fourth generation cephalosporins (cefuroxime, ceftriaxone, cefotaxime, cefixime, cefepime)	Very low (<0.5–1%)	Different R1 side chains	Structure-based	ℹ️ Generally safe in penicillin-allergic patients. First dose under observation if anaphylaxis history. Ceftriaxone is the most commonly used alternative in India.
Carbapenems (meropenem, imipenem, ertapenem)	Very low (<1%)	Different ring structure	Structure-based	ℹ️ Safe with first-dose observation.
Monobactams (aztreonam)	None (0%)	Completely different ring structure	No structural overlap	✅ Safe in penicillin allergy. Limited availability in India.
Non-beta-lactams (macrolides, fluoroquinolones, tetracyclines, aminoglycosides, metronidazole, nitrofurantoin)	None	No structural relationship	—	✅ Safe alternatives — no cross-reactivity.

ℹ️ Amoxicillin-specific cross-reactivity note: Amoxicillin has an amino group on the R1 side chain that is identical to the R1 side chain of cephalexin and cefadroxil. This means the cross-reactivity between amoxicillin specifically and cephalexin/cefadroxil specifically (~2–4%) is HIGHER than the general penicillin-cephalosporin cross-reactivity rate (~1–2%). If a patient’s allergy is specifically to amoxicillin (not to benzylpenicillin or other penicillins), cephalexin and cefadroxil should be specifically avoided. Other cephalosporins with different R1 side chains (cefuroxime, ceftriaxone, cefixime) carry lower risk.

ℹ️ Practical approach in India for “amoxicillin allergy” history:

Same principles as described in the benzylpenicillin monograph:

Vague history (“I had a rash to Augmentin/Mox”): Clarify: (a) What was the reaction? (rash vs urticaria vs angioedema vs GI upset); (b) How soon after taking the drug? (within 1 hour → more likely IgE-mediated; after >72 hours → likely delayed non-IgE); © Was the patient also ill with a viral infection? (viral exanthem misattributed to drug); (d) Was it amoxicillin alone or amoxicillin-clavulanate? (cholestatic hepatitis from co-amoxiclav does NOT contraindicate amoxicillin alone).
Convincing IgE-mediated history: ⛔ Avoid ALL penicillins. Use alternatives appropriate to the indication.
EBV-associated rash to amoxicillin: ⚠️ This is NOT a penicillin allergy. Document carefully: “Aminopenicillin rash in the setting of EBV infection — NOT IgE-mediated penicillin allergy. Penicillins may be used in future.” This documentation protects the patient from lifelong inappropriate penicillin avoidance.
Penicillin allergy de-labelling: Formal penicillin skin testing (available at select Indian tertiary centres — AIIMS, PGI, CMC Vellore, select allergy clinics) can safely de-label >90% of patients who carry a false “penicillin allergy” label. Consider referral for testing when the patient has a critical need for penicillin (RF prophylaxis, syphilis in pregnancy, endocarditis).

CAUTIONS

⚠️ HIGH-PRIORITY CAUTIONS (serious harm possible without active monitoring or dose adjustment):

Condition	Risk	Required Monitoring / Action
⚠️ Renal impairment (eGFR <30 mL/min)	Amoxicillin is 60–70% renally excreted as unchanged drug. In severe CKD, accumulation occurs with standard dosing. Risk of crystalluria at very high urinary concentrations (rare but documented — amoxicillin crystals precipitate in acidic, concentrated urine). Neurotoxicity is extremely rare with oral dosing (unlike high-dose IV benzylpenicillin) but theoretically possible at very high accumulation levels.	⚠️ Dose reduction required — see RENAL ADJUSTMENT. Maintain adequate hydration (reduces crystalluria risk). Monitor for GI adverse effects (diarrhoea — may be more pronounced with accumulation).
⚠️ Non-severe penicillin allergy history (delayed maculopapular rash >1 hour after administration, GI upset — NOT IgE-mediated)	These patients are at risk of being permanently and inappropriately labelled “penicillin-allergic.” The reaction was most likely NOT IgE-mediated and does NOT predict future anaphylaxis. However, without formal allergy assessment, there remains a small residual uncertainty.	Document the nature of the previous reaction precisely. If the indication for amoxicillin is important and long-term (RF prophylaxis via the penicillin class), refer for formal penicillin allergy assessment (skin prick test + intradermal test) at a tertiary centre. If testing is not available: administer the first dose under observation (minimum 30 minutes in a clinic with anaphylaxis management available).
⚠️ Suspected or confirmed infectious mononucleosis (EBV)	See Contraindications above. Aminopenicillin rash in ~70–100% of EBV patients. NOT an allergy but has serious consequences if mislabelled.	⚠️ If pharyngitis could be EBV (atypical features, hepatosplenomegaly, generalised lymphadenopathy, age 15–25 years, prominent fatigue): check monospot/EBV serology BEFORE prescribing amoxicillin. If EBV confirmed: do NOT prescribe amoxicillin.
⚠️ Concurrent methotrexate therapy	Amoxicillin competes with methotrexate for OAT1/OAT3-mediated renal tubular secretion → reduced methotrexate clearance → increased methotrexate toxicity risk (myelosuppression, mucositis, nephrotoxicity).	⚠️ Avoid concurrent use with high-dose methotrexate (oncology) if possible. For low-dose methotrexate (rheumatology): monitor CBC and renal function more frequently during the amoxicillin course. See MAJOR DRUG INTERACTIONS.
⚠️ Patients receiving amoxicillin for UTI based on empirical prescribing (without culture)	>60–70% of E. coli in India are resistant to amoxicillin (ICMR AMR data). Empirical amoxicillin for UTI will fail in the majority of cases → delayed treatment → risk of progression to pyelonephritis/sepsis.	⛔ Do NOT use amoxicillin empirically for UTI in India. Use only as directed therapy when culture confirms susceptibility. Use nitrofurantoin (uncomplicated cystitis) or culture-guided therapy as alternatives.

STANDARD CAUTIONS (conditions needing awareness but carrying lower risk):

Condition	Notes
History of antibiotic-associated diarrhoea	Amoxicillin commonly causes mild diarrhoea (5–10%). Patients with prior antibiotic-associated diarrhoea may be more susceptible. Counsel about maintaining hydration. If severe or bloody diarrhoea develops: stop amoxicillin, test for C. difficile, and treat accordingly.
Patients on oral contraceptives	ℹ️ NO interaction. Amoxicillin does NOT reduce the efficacy of combined oral contraceptives — this myth has been definitively debunked. Only rifampicin (CYP3A4 inducer) reliably reduces OCP efficacy. See MODERATE INTERACTIONS.
Phenylketonuria (PKU)	Some amoxicillin chewable tablets and oral suspensions may contain aspartame (a phenylalanine source). Check the product insert/label if prescribing for a child with PKU. Standard capsules and film-coated tablets do NOT contain aspartame.
Diabetes mellitus	Some oral suspensions contain sucrose (up to 3 g per 5 mL dose in some formulations). At standard dosing volumes (5–10 mL per dose), the sugar load is negligible for glycaemic control. Sugar-free formulations are available from some manufacturers.
Patients on warfarin	Modest INR increase possible (see MODERATE INTERACTIONS). Monitor INR if concurrent use >5 days.
Superinfection risk	Prolonged or repeated amoxicillin courses may cause oral/vaginal candidiasis. Broad-spectrum aminopenicillin activity (compared to natural penicillins) causes more disruption of gut flora → higher risk of superinfection (including C. difficile) than phenoxymethylpenicillin.
G6PD deficiency	No significant haemolytic risk with amoxicillin. Safe to use.
Inflammatory bowel disease	Antibiotics may alter gut microbiome and theoretically affect IBD. Use with awareness. No specific contraindication.

PREGNANCY

Parameter	Details
Overall safety statement	✅ Safe in pregnancy — all trimesters. Amoxicillin is one of the safest and most extensively studied antibiotics in pregnancy. Decades of clinical experience and multiple large epidemiological studies (including >100,000 pregnancy exposures in registry data) have confirmed no increased risk of congenital malformations, spontaneous abortion, stillbirth, preterm birth, or low birth weight. (Former US-FDA Category B.) Amoxicillin is among the first-choice antibiotics for treating infections during pregnancy in Indian and international obstetric practice.
Teratogenicity window	No teratogenic risk at any gestational age. Safe throughout pregnancy including the critical organogenesis period (weeks 3–8 post-conception).
Trimester-specific risks	All trimesters: Safe. No trimester-specific concerns.
Specific indications in pregnancy	(a) UTI in pregnancy (uncomplicated cystitis, asymptomatic bacteriuria, pyelonephritis — if organism is amoxicillin-susceptible) — safe and effective first-line option. ⚠️ Note: empirical use for UTI has the same resistance limitation as in non-pregnant patients — culture guidance is recommended. (b) GAS pharyngitis — safe first-line. © Dental infections — safe. (d) Chlamydial infection in pregnancy (alternative to azithromycin) — see Secondary Indication 6 in Part 2. (e) Pneumonia in pregnancy — safe first-line for mild CAP. (f) H. pylori eradication — rarely indicated in pregnancy but amoxicillin component is safe; clarithromycin safety in pregnancy is less well established. (g) Endocarditis prophylaxis — safe (single dose).
Preferred alternatives in pregnancy	Not needed — amoxicillin is ITSELF one of the preferred antibiotics in pregnancy. If penicillin allergy: cephalosporins (cephalexin, cefuroxime — with appropriate allergy precautions), erythromycin, azithromycin. Avoid: doxycycline (⛔ contraindicated — tooth/bone effects), fluoroquinolones (⛔ contraindicated — cartilage toxicity), co-trimoxazole (avoid in first trimester — folate antagonism; avoid near term — kernicterus risk).
What to monitor	Standard antenatal care. No drug-specific maternal or fetal monitoring required.
Pre-conception counselling	No specific pre-conception concerns. No washout period.
Contraception requirement	Not required. ℹ️ Amoxicillin does NOT reduce OCP efficacy.

Pregnancy Prevention Programme / Registry:

Not applicable — amoxicillin is safe in pregnancy.

Fertility Effects:

No known effect on male or female fertility. No impact on spermatogenesis, ovulation, or hormonal function.

LACTATION

Parameter	Details
Compatibility with breastfeeding	✅ Compatible — safe during breastfeeding. Amoxicillin is excreted into breast milk in small quantities. Widely used during lactation worldwide and in India without reported adverse effects on breastfed infants. Compatible with breastfeeding per all major references (LactMed, Hale’s, IAP, WHO).
Drug levels in milk	Low. Milk:plasma ratio approximately 0.014–0.043. The relative infant dose (RID) is estimated at ~1% of the maternal weight-adjusted dose — well within the safe range (<10%). The infant receives negligible drug exposure through breast milk.
What to monitor in infant	Routine monitoring only. Theoretical concerns: (a) mild diarrhoea (most commonly reported — due to disruption of infant gut flora); (b) oral thrush (candidiasis — rare); © allergic sensitisation (theoretical — no clinical evidence that breast milk amoxicillin exposure causes later penicillin allergy); (d) nappy/diaper rash (secondary to diarrhoea — if diarrhoea occurs). These effects are uncommon and mild.
Preferred alternatives during lactation	Not needed — amoxicillin is itself safe during lactation.
Timing advice	Not required — compatible without timing restrictions. The very low milk:plasma ratio means that timing doses around feeds provides negligible additional benefit.

Effect on milk production:

No known effect on milk production. No prolactin-related effects. Amoxicillin does not suppress or enhance lactation.

Temporary incompatibility guidance:

Not applicable — fully compatible with breastfeeding at all times. No need to withhold breastfeeding, pump and discard, or time doses.

ELDERLY

Definition: ≥60 years (Indian Census / National Programme for Health Care of the Elderly).

Parameter	Details
Recommended starting dose	Same as younger adults for most indications. Amoxicillin does NOT require age-based dose reduction per se. However, dose adjustment for renal function (which declines with age) is the primary consideration — calculate eGFR and adjust if <30 mL/min (see RENAL ADJUSTMENT). At standard doses (500 mg TDS) in elderly with eGFR >30: no adjustment needed.
Titration	Not applicable — antibiotic dosing is not titrated.
Key risks in elderly	1. Renal function decline — the ONLY pharmacokinetically significant consideration. Age-related GFR decline may reduce amoxicillin clearance. A “normal” serum creatinine in an elderly patient may mask a significantly reduced eGFR (due to lower muscle mass). Always calculate eGFR. At standard oral doses with eGFR >30, amoxicillin’s wide therapeutic index means modest accumulation is clinically insignificant. 2. Diarrhoea — elderly patients (especially those on PPIs, recent hospitalisation, or prior antibiotics) are at higher risk of C. difficile infection during any antibiotic course. Monitor stool frequency. If ≥3 watery stools/day or bloody diarrhoea: stop amoxicillin, test for C. difficile toxin. 3. Superinfection — oral and vaginal candidiasis (more common in elderly patients on dentures, with diabetes, or on inhaled corticosteroids). 4. Polypharmacy — check for interactions (very few with amoxicillin — see DRUG INTERACTIONS). Warfarin interaction is the most clinically relevant in elderly polypharmacy. 5. Adherence — elderly patients may have difficulty with multiple daily dosing (TDS or QID). BD regimens (where appropriate — e.g., 500 mg BD for pharyngitis, 875 mg BD for sinusitis) improve adherence. Consider dispersible tablets for patients with dysphagia.

Anticholinergic Cognitive Burden (ACB):

ℹ️ Amoxicillin has NO anticholinergic properties. ACB Score: 0. No contribution to anticholinergic burden. No cognitive impairment risk.

Beers Criteria / STOPP-START Relevance:

Amoxicillin is NOT listed in the Beers Criteria or STOPP/START criteria as a drug to avoid in elderly patients. It is a safe and appropriate antibiotic for elderly patients.

Deprescribing Guidance:

Not applicable for amoxicillin — it is prescribed as finite antibiotic courses (5–14 days) or as single doses (endocarditis prophylaxis), not as chronic therapy. There is no scenario where amoxicillin requires deprescribing in the traditional sense. Complete the prescribed course and stop — no tapering needed.

ℹ️ However: If an elderly patient is receiving repeated or prolonged courses of amoxicillin (e.g., recurrent UTIs, recurrent bronchitis), reassess: (a) Is the diagnosis correct? (b) Is the pathogen truly susceptible? © Are there preventive measures being missed? (d) Is an alternative approach (vaccination, prophylaxis, behavioural measures) more appropriate than repeated treatment courses?

MAJOR DRUG INTERACTIONS

⛔ Interactions that are contraindicated, can cause life-threatening adverse events, or require mandatory dose adjustment / alternative drug selection.

ℹ️ Amoxicillin has VERY FEW clinically significant drug interactions. It is not metabolised by CYP450 enzymes, does not induce or inhibit CYP450, and has no significant pharmacokinetic drug-drug interactions mediated by hepatic metabolism. The limited interaction profile is confined to:

Interacting Drug/Substance	Mechanism	Clinical Effect	Onset Type	Action Required
⚠️ Methotrexate	Amoxicillin (like all penicillins) competes with methotrexate for OAT1/OAT3-mediated renal tubular secretion → reduced methotrexate clearance → increased methotrexate plasma levels and prolonged exposure	⚠️ Increased methotrexate toxicity — myelosuppression (pancytopaenia), mucositis, nephrotoxicity, hepatotoxicity. Risk is highest with high-dose methotrexate (oncology — 1–12 g/m²). Also clinically relevant with low-dose methotrexate (rheumatology — 7.5–25 mg/week) — case reports of fatal pancytopaenia from this combination exist.	Gradual onset — over 24–72 hours as methotrexate accumulates	⚠️ Avoid concurrent use with high-dose methotrexate if possible. If unavoidable: monitor methotrexate levels closely, monitor renal function, watch for methotrexate toxicity (mouth ulcers are an early sign). For low-dose methotrexate (rheumatology): ⚠️ This combination is very commonly encountered in Indian practice (RA patient develops an infection). Do NOT reflexively avoid amoxicillin — it is often the best antibiotic for the infection. Instead: (a) monitor CBC weekly during and for 1 week after the amoxicillin course; (b) check renal function; © hold methotrexate during the acute infection if the patient is systemically unwell (many rheumatologists recommend holding MTX during acute febrile illness regardless of antibiotic choice); (d) educate the patient to report mouth ulcers, unusual bruising, or sore throat immediately.
⚠️ Allopurinol	Mechanism incompletely understood. Concurrent use of aminopenicillins (amoxicillin, ampicillin) with allopurinol increases the incidence of skin rash — estimated ~3-fold increase. The mechanism may involve: (a) immunomodulatory effect of allopurinol enhancing drug hypersensitivity; (b) accumulation of drug/metabolite due to shared renal transport.	⚠️ Increased rash incidence (~5–10% with concurrent use vs ~1–3% with amoxicillin alone). The rash is typically maculopapular (non-IgE-mediated) but can occasionally be severe (SJS/TEN — very rare).	Gradual onset — rash typically appears 5–14 days after starting the combination	⚠️ Be aware of this interaction. Allopurinol is very commonly prescribed in India (high gout prevalence). If a patient on allopurinol needs amoxicillin: (a) counsel that rash is more likely; (b) if rash develops, it is most likely due to the drug combination, NOT a true penicillin allergy — do NOT label the patient as penicillin-allergic based solely on a rash that occurred while on concurrent allopurinol; © stop amoxicillin if rash is extensive, pruritic, or associated with systemic symptoms; (d) if the patient needs penicillin in the future (without allopurinol), it may be safely given (the rash was likely allopurinol-facilitated, not a true penicillin allergy). If alternative antibiotic is preferred to avoid the rash issue: use azithromycin, cephalexin, or doxycycline (indication-dependent).
⚠️ Warfarin and other vitamin K antagonists	(a) Amoxicillin suppresses vitamin K-producing gut flora → reduced vitamin K synthesis → potentiation of warfarin’s anticoagulant effect → increased INR. (b) Amoxicillin may modestly inhibit CYP2C9 in some studies (the enzyme that metabolises the more potent S-warfarin enantiomer) — clinical significance is debated.	⚠️ Increased INR / bleeding risk. The effect is usually modest (INR increase of 0.5–1.5 points) but can occasionally be clinically significant, especially in elderly patients on stable warfarin doses.	Gradual onset — over 3–7 days of concurrent use	⚠️ Monitor INR within 3–5 days of starting amoxicillin in a patient on warfarin. Recheck INR at the end of the antibiotic course (INR may return to baseline). Adjust warfarin dose if INR rises significantly above target. ℹ️ In Indian practice, many patients on warfarin (for RHD with AF, prosthetic valves) may need amoxicillin for infections — this interaction is frequently encountered. Do NOT avoid amoxicillin because of warfarin — simply monitor INR more frequently.

Food-Drug Interactions:

Substance	Mechanism	Clinical Effect	Action
Food (any meal)	Delays rate of absorption (Tmax shifted by ~30 min) but does NOT significantly reduce extent of absorption (AUC unchanged).	ℹ️ NO clinically significant reduction in efficacy when taken with food. This is a major advantage over phenoxymethylpenicillin and ampicillin.	✅ May be taken with or without food. Taking with food may reduce GI upset (nausea).
Dairy products (milk, curd/yogurt, paneer)	No significant chelation or absorption interaction (unlike fluoroquinolones or tetracyclines).	ℹ️ No interaction. Amoxicillin can be taken with milk or dairy.	✅ No restriction.

Herb-Drug and Traditional Medicine Interactions:

No documented clinically significant herb-drug interactions with amoxicillin. The drug is not metabolised by CYP450 enzymes and its renal clearance mechanism is not significantly affected by commonly used Indian herbal preparations.

MODERATE DRUG INTERACTIONS

Interactions that usually can be managed with monitoring or minor dose adjustment.

Interacting Drug/Substance	Mechanism	Clinical Effect	Onset Type	Action Required
Probenecid	Probenecid inhibits OAT1/OAT3-mediated renal tubular secretion of amoxicillin → reduced renal clearance → increased amoxicillin serum levels (~2-fold increase in AUC) and prolonged half-life.	Increased amoxicillin levels. This is a therapeutically beneficial interaction that was historically exploited to boost penicillin levels. Occasionally still used intentionally (e.g., single-dose amoxicillin 3 g + probenecid 1 g for uncomplicated gonorrhoea — historical regimen; now largely replaced by ceftriaxone due to gonococcal resistance).	Acute onset — within 1–2 hours	ℹ️ If a patient is already on probenecid for gout and receives amoxicillin: expect higher and more prolonged amoxicillin levels — usually beneficial, not harmful (wide therapeutic index). No dose adjustment needed unless severe renal impairment is also present.
Oral contraceptives (combined OCP)	ℹ️ NO pharmacokinetic interaction. The historical concern that amoxicillin reduces OCP efficacy by disrupting gut flora → reduced enterohepatic circulation of ethinyl oestradiol has been definitively debunked by pharmacokinetic studies and large population studies.	ℹ️ NO reduction in OCP efficacy. Only rifampicin (and rifabutin) — potent CYP3A4 inducers — reliably reduce OCP efficacy.	—	ℹ️ No additional contraception needed. ⚠️ Actively debunk this myth when counselling patients — it is extremely prevalent in Indian practice (among doctors, pharmacists, and patients). Inappropriate advice to use barrier contraception causes anxiety, non-adherence to OCPs, and sometimes unintended pregnancy.
Tetracyclines (doxycycline, tetracycline)	Bacteriostatic agents may theoretically antagonise the bactericidal activity of amoxicillin (which requires actively dividing bacteria for cell-wall-synthesis inhibition).	Theoretical reduced bactericidal efficacy. Clinical significance is debated — limited evidence of actual clinical treatment failure from this combination.	Acute onset (pharmacodynamic)	ℹ️ Avoid concurrent use when possible — use one or the other. In practice, the drugs cover different organisms and are rarely co-prescribed for the same infection. Exception: H. pylori quadruple therapy (where amoxicillin + tetracycline + bismuth + PPI is a recognized regimen — the theoretical antagonism does not appear to be clinically significant in this specific context, possibly because the combination of multiple agents and the acidic gastric environment modify the interaction).
Mycophenolate mofetil (MMF)	Amoxicillin may reduce the enterohepatic recirculation of mycophenolic acid (MPA — the active metabolite of MMF) by disrupting gut flora that hydrolyse the MPA glucuronide conjugate → reduced MPA reabsorption → decreased MPA levels.	⚠️ Potentially reduced mycophenolate efficacy — risk of transplant rejection or flare of autoimmune disease.	Gradual onset — over days of concurrent use	⚠️ Monitor for signs of reduced immunosuppressive efficacy. In transplant patients: consider checking MPA trough levels if available. If the antibiotic course is short (5–7 days), the clinical impact is usually minor. Alert the transplant physician. ℹ️ In Indian transplant practice (increasing renal and liver transplant volumes), this interaction is relevant — many transplant recipients on MMF develop infections requiring amoxicillin.
Oral typhoid vaccine (Ty21a — live attenuated)	Amoxicillin has activity against Salmonella → may reduce viability of the live vaccine organisms → potentially reduced vaccine efficacy.	Potentially reduced vaccine efficacy.	Acute onset	⚠️ Complete the antibiotic course at least 3 days before administering oral typhoid vaccine. Injectable typhoid vaccine (Vi polysaccharide — Typhim Vi) is NOT affected (inactivated vaccine — can be given concurrently).
Metformin	Both drugs are substrates of renal organic cation/anion transporters — theoretical competition for renal clearance. Amoxicillin may slightly alter metformin clearance.	Theoretical — clinical significance uncertain. No documented clinically significant interaction.	—	ℹ️ Likely clinically insignificant. No dose adjustment needed. In Indian practice, this combination is extremely common (diabetic patient with infection). Monitor blood glucose if concerned — the acute infection itself is more likely to disrupt glycaemic control than the antibiotic interaction.
Anticoagulants — DOACs (dabigatran, rivaroxaban, apixaban)	No significant pharmacokinetic interaction (amoxicillin does not affect CYP3A4 or P-glycoprotein). Theoretical gut flora effect on vitamin K is less relevant for DOACs (which do not depend on vitamin K for their mechanism).	ℹ️ No significant interaction. Unlike warfarin, DOACs are NOT affected by changes in vitamin K status.	—	✅ No dose adjustment or additional monitoring needed.
Antacids (aluminium/magnesium hydroxide), H₂ blockers, PPIs	PPIs and H₂ blockers increase gastric pH. Amoxicillin is acid-stable — increased pH does NOT impair its absorption (unlike some other drugs). Antacid cations (Al³⁺, Mg²⁺) do NOT chelate significantly with amoxicillin (unlike fluoroquinolones or tetracyclines).	ℹ️ No significant interaction. Amoxicillin absorption is NOT affected by acid-suppressing drugs. This is relevant for H. pylori eradication regimens where amoxicillin is co-administered with a PPI — the PPI does NOT impair amoxicillin absorption.	—	✅ No separation of doses needed.
Isotretinoin	Data limited. Some case reports suggest increased risk of benign intracranial hypertension (pseudotumour cerebri) when tetracyclines are combined with isotretinoin — but this interaction is specific to tetracyclines, NOT amoxicillin.	ℹ️ No documented interaction between amoxicillin and isotretinoin.	—	✅ Safe to co-administer.

COMMON ADVERSE EFFECTS

ℹ️ Amoxicillin is one of the best-tolerated oral antibiotics in clinical use. Its adverse-effect profile is dominated by GI effects (disruption of gut flora — a class effect of all oral antibiotics) and hypersensitivity reactions (a class effect of all penicillins). Serious adverse effects are rare. The drug has been in use since 1972 and has an extensive safety record.

Frequency classification source: Derived from clinical trial data, post-marketing surveillance, CDSCO product inserts, and published pharmacovigilance analyses. Amoxicillin has been used in billions of treatment courses worldwide — the safety profile is well characterised.

Very Common (≥10%):

Adverse Effect	System	Notes
Diarrhoea	GI	The most frequently reported adverse effect (~10–20% at standard doses; higher at high doses — 80–90 mg/kg/day). Due to disruption of intestinal flora by the broad-spectrum aminopenicillin activity. Usually mild, self-limiting, and does NOT require discontinuation. Dose-dependent: significantly more common at high doses (AOM regimen 80–90 mg/kg/day in children: diarrhoea rates ~15–25%) vs standard doses (40–50 mg/kg/day: ~5–10%). ℹ️ Amoxicillin causes MORE diarrhoea than phenoxymethylpenicillin (broader spectrum → more gut flora disruption) but LESS diarrhoea than amoxicillin-clavulanate (the clavulanic acid component is the primary driver of co-amoxiclav-associated diarrhoea). Management: maintain hydration; advise ORS if diarrhoea is significant; probiotic supplementation (Saccharomyces boulardii or Lactobacillus — commonly co-prescribed in India, though evidence for antibiotic-associated diarrhoea prevention is moderate). ⚠️ In infants and toddlers: diarrhoea from amoxicillin commonly causes or worsens nappy/diaper rash — advise barrier cream (zinc oxide) prophylactically during the antibiotic course.

Common (1–10%):

Adverse Effect	System	Notes
Nausea	GI	Reported in ~3–5%. Dose-dependent. Less common when taken with food (a practical advantage over phenoxymethylpenicillin, which must be taken on an empty stomach). Usually mild and self-limiting.
Vomiting	GI	Reported in ~1–3%. More common in children (especially with large-volume suspension doses at high-dose regimens). If the child vomits within 30 minutes of a dose: repeat the dose. If vomiting occurs >30 minutes after: do NOT repeat (drug is likely already absorbed).
Maculopapular rash (non-urticarial, delayed — Type IV hypersensitivity)	Dermatological / Immunological	Approximately 3–5% of all patients receiving amoxicillin. Onset typically >72 hours after starting (often day 5–10 of the course). Non-pruritic or mildly pruritic maculopapular eruption, usually on trunk and extremities. ⚠️ This is NOT IgE-mediated anaphylaxis and does NOT predict future anaphylaxis. However, it is very frequently mislabelled as “penicillin allergy” in Indian medical records, resulting in lifelong penicillin avoidance — with significant clinical consequences (exclusion from RF prophylaxis, syphilis treatment, endocarditis treatment). ⚠️ EBV-associated aminopenicillin rash: In patients with concurrent infectious mononucleosis (EBV), the rash incidence rises to ~70–100% — see Contraindications. Documentation guidance: Record as: “Delayed maculopapular rash to amoxicillin (onset day [X]) — Type IV non-IgE-mediated reaction — NOT anaphylaxis — penicillin NOT absolutely contraindicated in future — formal allergy testing recommended before labelling as penicillin-allergic.”
Oral candidiasis (thrush)	Infectious / Oral	Reported in ~1–3%. Due to suppression of normal oral bacterial flora → Candida overgrowth. More common with prolonged courses (>7 days), high doses, concurrent inhaled corticosteroids, diabetes, immunosuppression, and denture use (elderly). Treat with topical nystatin oral suspension (1 mL QID swish-and-swallow) or miconazole oral gel.
Vaginal candidiasis	Infectious / Gynaecological	Reported in ~1–5% of women. Same mechanism as oral candidiasis. Treat with topical clotrimazole pessary/cream or single-dose oral fluconazole 150 mg.
Abdominal pain / cramps	GI	Mild. ~1–3%. Related to altered gut motility and flora disruption.
Headache	CNS	~1–2%. Mild. Usually coincidental with the underlying infection.
Taste disturbance	Oral	Uncommon with capsules/tablets. May occur with oral suspension — most Indian brands are well-flavoured and this is rarely significant.

Dose-Response Thresholds:

Adverse Effect	Dose Threshold
Diarrhoea	Dose-dependent: ~5–10% at 40–50 mg/kg/day; ~15–25% at 80–90 mg/kg/day (high-dose AOM/pneumonia regimen). Higher total daily doses → more flora disruption → more diarrhoea.
Nausea/vomiting	More common at higher individual doses (1 g per dose vs 500 mg per dose). Taking with food reduces nausea without compromising absorption.
Rash	NOT dose-dependent — immune-mediated (occurs at any dose).
Candidiasis	More common with prolonged courses (>7 days) and higher doses.

SERIOUS ADVERSE EFFECTS

⚠️ Rare but clinically important — may require immediate intervention, discontinuation, or hospitalisation.

Serious Adverse Effect	Approximate Frequency	Details	Action Required
⚠️ Anaphylaxis (IgE-mediated Type I hypersensitivity)	~1–5 per 10,000 treatment courses (~0.01–0.05%); fatality rate ~1 per 50,000–100,000 courses	The most serious adverse effect of any penicillin. Onset: within minutes to 1 hour of oral administration (may be slightly delayed compared to IV penicillin due to oral absorption kinetics). Classic features: urticaria, angioedema (swelling of face/lips/tongue/throat), bronchospasm (wheeze, dyspnoea), laryngeal oedema (stridor), hypotension, cardiovascular collapse. ℹ️ Anaphylaxis after ORAL amoxicillin is less common than after parenteral penicillin but CAN occur and can be fatal.	⛔ Immediate treatment: Adrenaline (epinephrine) 1:1000 IM — 0.5 mg IM (adult), 0.01 mg/kg IM (child, max 0.3–0.5 mg). Repeat every 5–15 min if needed. High-flow O₂, IV access, IV NS bolus, antihistamine (chlorpheniramine 10 mg IV / diphenhydramine 50 mg IV), hydrocortisone 200 mg IV. Observe ≥6 hours (biphasic reaction risk). ✅ Adrenaline availability: Widely available in India — must be present at every healthcare facility. ⚠️ Report to PvPI.
⚠️ Serum sickness-like reaction (Type III hypersensitivity)	~1–2% with prolonged courses	Immune complex-mediated. Onset: 7–21 days after starting. Features: fever, urticaria or maculopapular rash, polyarthralgia/arthritis, lymphadenopathy. Lab: low complement, elevated ESR.	Stop amoxicillin. NSAIDs for joint pain, antihistamines for urticaria, prednisolone (0.5–1 mg/kg/day × 5–7 days) for severe symptoms. Self-limiting within 1–3 weeks. ⚠️ Report to PvPI.
⚠️ Acute interstitial nephritis (AIN)	Very rare (<0.1%)	Immune-mediated renal inflammation. Onset: 1–4 weeks. Features: fever, rash, eosinophilia, rising creatinine, eosinophiluria.	Stop amoxicillin. Renal function usually recovers. Corticosteroids may help in severe cases. Nephrology consultation. Avoid ALL penicillins in future. ⚠️ Report to PvPI.
⚠️ Clostridioides difficile infection (CDI)	Uncommon but clinically important — amoxicillin causes more CDI risk than narrow-spectrum penicillins (phenoxymethylpenicillin) but less than amoxicillin-clavulanate, cephalosporins, or fluoroquinolones	Antibiotic-associated disruption of gut flora → C. difficile overgrowth → toxin-mediated colitis. Risk factors: elderly, recent hospitalisation, PPI use, prior antibiotics, immunocompromised. Presents as: watery diarrhoea (≥3 stools/day), abdominal cramps, fever, leucocytosis. Severe: toxic megacolon, perforation, sepsis.	Stop amoxicillin. Diagnose: stool C. difficile toxin assay (GDH + toxin A/B EIA or NAAT). Treat: oral vancomycin 125 mg QID × 10 days (first-line per current guidelines) or oral metronidazole 500 mg TDS × 10 days (second-line; still commonly used first-line in India due to cost and vancomycin capsule availability). Fidaxomicin 200 mg BD × 10 days (available at limited Indian centres; expensive). ⚠️ Report to PvPI for severe cases.
⚠️ EBV-associated aminopenicillin rash	~70–100% in patients with concurrent infectious mononucleosis	See Contraindications section. Widespread maculopapular rash — NOT IgE-mediated allergy. The rash itself is self-limiting (resolves in 3–7 days after stopping amoxicillin) and does NOT require specific treatment beyond antihistamines for pruritus. ⚠️ The clinical harm is primarily from MISLABELLING the patient as “penicillin-allergic” — this can have lifelong consequences.	Stop amoxicillin. Antihistamines for pruritus. ⚠️ Document clearly: “Aminopenicillin rash in the setting of confirmed/suspected EBV infection. This is NOT an IgE-mediated penicillin allergy. The patient is NOT penicillin-allergic. Future penicillin use is NOT contraindicated.” Educate the patient/family accordingly.
Haemolytic anaemia (Coombs-positive)	Extremely rare — isolated case reports	IgG anti-penicillin antibodies → complement activation → haemolysis. Much more likely with high-dose IV penicillin than oral amoxicillin.	Stop amoxicillin. Monitor Hb, reticulocytes, LDH, haptoglobin. Transfusion if severe. ⚠️ Report to PvPI.
Stevens-Johnson Syndrome (SJS) / Toxic Epidermal Necrolysis (TEN)	Extremely rare — isolated case reports	Severe mucocutaneous reaction. Warning signs: targetoid lesions, mucosal ulceration (oral, ocular, genital), skin pain/tenderness, fever.	⛔ Medical emergency. Immediate discontinuation. Hospitalisation (burns/dermatology unit). Supportive care. Avoid ALL penicillins (and potentially all beta-lactams) for life. ⚠️ Report to PvPI.
Crystalluria	Very rare — primarily at very high doses in patients with renal impairment and dehydration	Amoxicillin crystals precipitate in concentrated, acidic urine → renal tubular obstruction → acute kidney injury. Risk factors: high-dose amoxicillin + severe CKD + dehydration + acidic urine.	Maintain adequate hydration during amoxicillin therapy (especially at high doses and in renal impairment). Alkalinise urine if crystalluria is suspected (sodium bicarbonate). Reduce dose in renal impairment. ⚠️ Report to PvPI.
Seizures	Extremely rare — at standard oral doses, virtually unreported. Theoretical risk only at massively supratherapeutic accumulation in severe renal failure.	Unlike high-dose IV benzylpenicillin, oral amoxicillin almost never causes seizures because oral bioavailability caps the achievable serum levels well below the neurotoxicity threshold.	If seizures occur in a patient on amoxicillin: (a) stop the drug; (b) check renal function (is the patient in unsuspected renal failure?); © look for other causes of seizures; (d) benzodiazepines for acute seizure management.

Antidote / Reversal Information:

Toxicity	Antidote	Dose	Availability in India
Anaphylaxis	Adrenaline (epinephrine) 1:1000 IM	Adult: 0.5 mg IM. Paediatric: 0.01 mg/kg IM (max 0.3–0.5 mg). Repeat every 5–15 min.	✅ Widely available.
Overdose (accidental ingestion of large amount)	No specific antidote. Supportive care.	Amoxicillin has a very wide therapeutic index. Massive overdose primarily causes GI symptoms (nausea, vomiting, diarrhoea). Crystalluria may occur. Maintain hydration. Haemodialysis can remove amoxicillin if needed (rarely necessary).	—
CDI	Oral vancomycin / Oral metronidazole	See above.	✅ Both available.

⚠️ Report ALL serious adverse effects to nearest ADR Monitoring Centre under PvPI (Pharmacovigilance Programme of India) or via the ADR reporting form on CDSCO website: https://www.ipc.gov.in.

MONITORING REQUIREMENTS

Baseline (Before Starting)

Parameter	Grade	Details
Penicillin allergy history	MANDATORY	Ask every patient/parent specifically about previous reactions to amoxicillin, augmentin, or any antibiotic. Clarify the nature, timing, and severity of any reported reaction (see Contraindications and Cautions for approach to allergy assessment).
Renal function	RECOMMENDED for: (a) high-dose regimens (80–90 mg/kg/day); (b) courses >7 days; © elderly patients; (d) patients with known or suspected CKD, diabetes, or hypertension. NOT required for: standard-dose short courses (5–7 days) in patients with no risk factors for renal impairment.	Check serum creatinine and calculate eGFR. Adjust dose if eGFR <30 (see RENAL ADJUSTMENT).
Infection-specific investigations	Varies by indication: (a) GAS pharyngitis: RADT or throat culture (recommended, not mandatory). (b) UTI: Urine culture (MANDATORY before amoxicillin for UTI — amoxicillin is NOT for empirical UTI). © Pneumonia: CXR (mandatory); sputum AFB/GeneXpert (mandatory in India if TB is a differential). (d) H. pylori: Confirmed diagnosis before treatment (mandatory). (e) AOM: Otoscopy (mandatory).	See individual indication-specific notes in Part 2 for details.
EBV screening (if pharyngitis may be mononucleosis)	RECOMMENDED in: young adults (15–25 years) with pharyngitis + tonsillar enlargement + cervical lymphadenopathy + fatigue + hepatosplenomegaly.	Monospot test (heterophile antibody) or EBV IgM serology before prescribing amoxicillin — to avoid EBV-associated aminopenicillin rash and subsequent false “penicillin allergy” labelling.
Methotrexate co-administration check	MANDATORY	If the patient is on methotrexate (rheumatology or oncology): document this. Plan monitoring (CBC, renal function) during the amoxicillin course. See MAJOR INTERACTIONS.

Resource-limited setting surrogates:

Parameter	Surrogate
Penicillin allergy assessment	Careful verbal history — minimum acceptable standard. Ask specifically, do not rely on passive disclosure.
Renal function	If creatinine cannot be checked: ask about known kidney disease, diabetes duration, oedema, reduced urine output. For standard-dose short courses in otherwise healthy patients, renal function testing is not essential.
EBV screening	If monospot is not available: clinical judgement. If the pharyngitis presentation is atypical (prominent fatigue, hepatosplenomegaly, diffuse lymphadenopathy, atypical lymphocytes on blood smear if available) — avoid amoxicillin and use azithromycin or supportive care instead.

After Initiation / Dose Change

Timing	Monitoring	Details
Day 2–3 of treatment	Clinical response assessment	Has the patient improved (reduced fever, reduced pain, improving symptoms)? If no improvement by 48–72 hours: reassess diagnosis and antibiotic choice.
During treatment	Monitor for diarrhoea	Counsel patient to report if diarrhoea becomes severe (≥3 watery stools/day), bloody, or associated with fever/cramps (concern for C. difficile).
End of course	Confirm course completion	For GAS pharyngitis (10-day course): verify that the full 10 days were completed.
If on concurrent warfarin	INR	Check INR within 3–5 days of starting amoxicillin. Recheck at end of course.
If on concurrent methotrexate	CBC, renal function	Check CBC weekly during amoxicillin course and for 1 week after.

Long-Term / Maintenance Monitoring

Not applicable for most amoxicillin indications (short treatment courses). For prophylaxis indications (post-splenectomy, SCD) using amoxicillin as an alternative to penicillin V: see phenoxymethylpenicillin monograph for ongoing monitoring guidance (adherence assessment, vaccination status review, clinical review for infection symptoms).

Therapeutic Drug Monitoring (TDM)

Not applicable. Amoxicillin does not have a defined therapeutic range and TDM is not performed in clinical practice. The drug has a very wide therapeutic index.

When to Stop Monitoring

Short treatment courses (5–14 days): Monitoring ends when the course is completed and the patient is clinically well. No post-course follow-up labs are needed (except: post-treatment throat culture for GAS pharyngitis in high-risk patients — optional; H. pylori eradication confirmation test at ≥4 weeks — recommended; UTI follow-up culture — recommended).
Concurrent warfarin: Recheck INR 3–5 days after stopping amoxicillin to ensure return to baseline.
Concurrent methotrexate: Check CBC 1 week after completing amoxicillin course.

PATIENT COUNSELLING

Written in simple language that a doctor can directly convey to the patient during consultation.

What this medicine is for:

“This medicine kills germs (bacteria) that are causing your infection. It works for throat infections, ear infections, chest infections, urine infections, stomach infections (H. pylori), and some skin infections.”

How to take it:

“Swallow the capsule/tablet with a full glass of water. You can take it with or without food — taking it with food is fine and may actually reduce stomach upset. If you are using the liquid medicine (syrup) for your child: shake the bottle well before every dose. Measure the dose carefully with the syringe or cup provided — not a kitchen spoon. If using dispersible tablets: drop the tablet in a small glass of water (about 2 tablespoons), wait until it dissolves completely, stir, and give the entire liquid to the child.”

What to do if you miss a dose:

“If you forget a dose, take it as soon as you remember. But if your next dose is within 4 hours (for three-times-daily dosing) or 6 hours (for twice-daily dosing), skip the missed dose. Never take two doses together. If you are taking this for a sore throat infection (10-day course), make sure you complete all 10 days — if you missed a day’s doses, add one extra day at the end.”

Common side effects to expect:

“You may have loose stools or mild diarrhoea — this is common and usually harmless. Drink plenty of water. If diarrhoea is very frequent or contains blood, contact your doctor. You may notice mild nausea — taking the medicine with food can help. Women may develop vaginal itching or discharge (yeast infection) — this can be treated with antifungal cream or a single tablet (fluconazole). Children may develop white patches in the mouth (oral thrush) — tell the doctor, this is easily treated.”

Warning signs — come to hospital IMMEDIATELY if you notice:

"⚠️ Go to the hospital RIGHT AWAY if you develop:

Difficulty breathing, swelling of face/lips/tongue/throat, or a widespread bumpy/itchy rash (hives) — this could be a serious allergic reaction (RARE)
Severe watery diarrhoea (more than 5 times a day) or bloody diarrhoea
Severe skin rash with blistering, or mouth sores
Yellowing of your eyes or skin (very rare with amoxicillin alone)
Reduced urination or dark-coloured urine (very rare)"

Things to avoid:

“There are no specific food restrictions with this medicine. You CAN drink milk and eat dairy products — they do NOT interfere with this medicine (unlike some other antibiotics). You do NOT need to avoid alcohol during a short course, though alcohol may worsen stomach upset.”

Storage:

“Store capsules/tablets in the original pack in a cool, dry place below 30°C. Keep away from moisture.”
“Liquid medicine (syrup): Keep in the fridge after mixing. If no fridge: keep in the coolest part of the house and use within 5 days. If kept in the fridge: use within 2 weeks. Throw away any leftover liquid after this.”
“Dispersible tablets: Store at room temperature — no fridge needed.”
“Keep all medicines away from children.”

Duration:

“For sore throat: Take for exactly 10 days — even if you feel completely well after 2–3 days. Stopping early can leave germs in your throat that may later harm your heart.”
“For ear infection, chest infection, urine infection, skin infection: Take for the number of days your doctor has prescribed (usually 5–7 days). Complete the full course.”
“For stomach germ (H. pylori): Take the full 14-day kit as prescribed. Take ALL the medicines in the kit, not just the amoxicillin.”

Follow-up:

“For most infections: return if your symptoms do not improve within 2–3 days, or if they get worse. For H. pylori: your doctor will order a breath test or stool test 4 weeks after you finish the medicines to check if the germ has been cleared. For urine infection: your doctor may order a repeat urine test to confirm the infection is gone.”

Common patient questions addressed:

Question	Answer
“Can I take this with my other medicines?”	“This medicine is safe with most other medicines. Tell your doctor if you are taking blood thinners (warfarin), medicines for arthritis/cancer (methotrexate), or gout medicines (allopurinol) — these may need extra monitoring.”
“Can I take this during fasting (Ramadan/Navratri)?”	“If twice daily: take at Suhoor and Iftar (or before your two meals). If three times daily: take at Suhoor, Iftar, and before sleeping (adjust spacing as evenly as possible). You can take it with food.”
“Will this affect my ability to drive/work?”	“No — this medicine does not cause drowsiness or affect concentration.”
“Is this medicine habit-forming?”	“No — antibiotics are not addictive.”
“Can I stop once I feel better?”	“⚠️ For sore throat (10-day course): ABSOLUTELY NOT — you MUST complete all 10 days to protect your heart. For other infections: complete the full course your doctor prescribed, even if you feel better earlier.”
“Is this the same as Augmentin?”	“No — Augmentin (amoxicillin + clavulanic acid) is a different, stronger medicine that covers more types of germs. Your doctor has prescribed plain amoxicillin because it is the right medicine for your infection — it is equally effective and causes less stomach upset than Augmentin.”
“Will this reduce the effect of my birth control pills?”	“⚠️ NO — this is a common myth. Amoxicillin does NOT reduce the effect of birth control pills. You do NOT need extra protection.”
“I was told I’m allergic to Amoxil/Mox — can I take this?”	“Tell your doctor exactly what happened when you took Amoxil/Mox. If you had a mild rash after several days, you are probably NOT truly allergic — your doctor may recommend an allergy test. If you had swelling of your face/throat or difficulty breathing, you should avoid this medicine.”

Caregiver / Family Counselling:

"If you are giving this medicine to a child:

Shake the bottle well before every dose — the medicine settles.
Measure carefully with the syringe or cup — NOT a kitchen spoon.
Complete all 10 days for sore throat — even if the child seems perfectly well.
Watch for rash — if a mild rash appears after a few days, it is usually not serious, but tell the doctor. If the child develops facial swelling, difficulty breathing, or severe widespread rash: go to the hospital immediately.
Diarrhoea is common — keep the child well hydrated with ORS. Use barrier cream (zinc oxide) on the nappy area to prevent rash.
Store the liquid in the fridge — mark the bottle with the date you mixed it and throw it away after 14 days (or 5 days if no fridge)."

India-specific adherence support:

Concern	Guidance
Cost-driven non-adherence	“Amoxicillin is one of the cheapest antibiotics available — a full 10-day course costs ₹30–80. Generic brands and Jan Aushadhi pharmacy options are available. If cost is a concern, ask your doctor about the cheapest generic brand.”
Premature discontinuation	“⚠️ This is the #1 problem with antibiotic use in India. Many patients stop their antibiotic after 2–3 days when they feel better. For sore throat, this can lead to rheumatic fever — a disease that damages the heart permanently. Take ALL 10 days.”
Self-medication culture	“In India, amoxicillin is often bought without a prescription from medical shops. This is inappropriate — using antibiotics without a doctor’s advice drives antibiotic resistance and may delay proper diagnosis. Always see a doctor before taking any antibiotic.”
Temperature-sensitive storage (suspension)	“Keep the liquid medicine in the fridge. If no fridge: use within 5 days and store in the coolest place in the house. In Indian summers (40°C+), the medicine spoils faster outside the fridge. Dispersible tablets do NOT need a fridge — they are ideal for areas without reliable refrigeration.”
Rural access	“Amoxicillin is available at virtually every pharmacy in India, including in villages and small towns. Government hospitals and Jan Aushadhi stores provide it at very low cost or free. If your exact brand is unavailable, any generic brand of amoxicillin is equally effective.”
Polypharmacy	Not typically applicable to amoxicillin (short courses, few interactions).

BRANDS AVAILABLE IN INDIA

Jan Aushadhi / PMBJP brands:

✅ Amoxicillin is available through Jan Aushadhi (PMBJP) stores — the drug is included in the PMBJP product catalogue. Capsules (250 mg, 500 mg), dispersible tablets (250 mg), and dry syrup (125 mg/5 mL, 250 mg/5 mL) are listed. Jan Aushadhi brands are the lowest-cost option.

Private / Commercial brands:

Brand Name	Manufacturer	Formulations	Availability
Mox	Ranbaxy / Sun Pharma	Capsules 250 mg, 500 mg; Dry syrup 125 mg/5 mL, 250 mg/5 mL	Widely available — one of the most recognised amoxicillin brands in India. Stocked at virtually all pharmacies nationwide.
Novamox	Cipla	Capsules 250 mg, 500 mg; Dry syrup 125 mg/5 mL, 250 mg/5 mL; DT 125 mg, 250 mg	Widely available — another leading brand.
Amoxil	GlaxoSmithKline (historical) / various	Capsules 250 mg, 500 mg	Moderate availability — historical brand name, less commonly stocked than Mox or Novamox currently.
Wymox	Pfizer (historical) / various	Capsules 250 mg, 500 mg	Limited availability currently.
SB-Mox / Amoxycillin DT (dispersible tablets — government supply)	Various WHO-prequalified manufacturers (including Indian manufacturers supplying NHM)	DT 250 mg	Government supply — widely distributed through NHM/NRHM, PHCs, CHCs, district hospitals. The standard paediatric amoxicillin formulation in government health facilities.
Generic Amoxicillin IP	Multiple Indian manufacturers (Alkem, Cipla, Mankind, Micro Labs, Lupin, Hetero, FDC Ltd, and others)	All formulations	Widely available — India has dozens of generic manufacturers. Generic brands are competitively priced and bioequivalent. Available nationwide including rural pharmacies.

FDC brands (most commonly prescribed):

FDC Brand	Composition	Manufacturer	Availability
Augmentin	Amoxicillin + Clavulanic acid	GlaxoSmithKline	Widely available — the most recognised co-amoxiclav brand. ⚠️ This is a SEPARATE drug — see amoxicillin-clavulanate monograph.
Clavam	Amoxicillin + Clavulanic acid	Alkem	Widely available
Moxikind-CV	Amoxicillin + Clavulanic acid	Mankind Pharma	Widely available
H. pylori eradication kits	Amoxicillin + Clarithromycin + PPI	Various manufacturers (HP Kit, Pylokit, etc.)	Widely available

CDSCO NSQ / Recall Alerts: Periodic Not of Standard Quality (NSQ) alerts for individual batches of generic amoxicillin products have been issued by CDSCO. Prescribers should verify against the latest CDSCO notifications at https://cdsco.gov.in. No widespread brand-level recall affecting major brands was identified at the time of this monograph.

PRICE RANGE (INR)

Prices as of June 2025. Verify current prices on NPPA/1mg/PharmEasy/Jan Aushadhi price lists as prices may change.

Formulation	Strength	Approximate Price Range (INR)	Notes
Capsules (branded — Mox, Novamox, etc.)	250 mg (strip of 10)	₹25–55 per strip (₹2.50–5.50 per capsule)
	500 mg (strip of 10)	₹50–100 per strip (₹5.00–10.00 per capsule)
Capsules (generic)	250 mg (strip of 10)	₹12–30 per strip (₹1.20–3.00 per capsule)	Government supply: ₹8–15 per strip.
	500 mg (strip of 10)	₹20–50 per strip (₹2.00–5.00 per capsule)	Government supply: ₹12–25 per strip.
Jan Aushadhi capsules	500 mg	₹10–20 per strip	Lowest price option.
Tablets (film-coated)	875 mg (strip of 6–10)	₹60–120 per strip	Used for high-dose BD regimens.
Dispersible tablets (DT)	250 mg (strip of 10)	₹15–35 per strip	✅ Excellent value. Government supply: ₹8–15. Jan Aushadhi: ₹8–15.
Dry syrup / Oral suspension	125 mg/5 mL (bottle — 30–60 mL)	₹20–45 per bottle
	250 mg/5 mL (bottle — 30–60 mL)	₹30–70 per bottle
Oral drops (paediatric)	100 mg/mL (bottle — 10–15 mL)	₹30–60 per bottle	Less commonly stocked.
Injection (if available — limited)	500 mg vial; 1 g vial	₹25–80 per vial	⚠️ Very limited availability as single-ingredient injection.

NPPA Price Control: ✅ Amoxicillin is listed in NLEM India 2022 and is subject to NPPA price control under the Drug Prices Control Order (DPCO). Ceiling prices are notified by NPPA and updated periodically.

PMBJP (Jan Aushadhi) availability: ✅ Available through Jan Aushadhi stores.

Per-Course Cost Estimates:

Scenario	Estimated Cost
GAS pharyngitis — 10-day course (500 mg BD)	Branded: ₹100–200. Generic: ₹40–100. Jan Aushadhi: ₹20–40.
GAS pharyngitis — paediatric 10-day course (250 mg BD suspension)	Branded: ₹30–70 (1 bottle). Generic: ₹20–45.
CAP — 5-day course (500 mg TDS)	Branded: ₹75–150. Generic: ₹30–75.
CAP — high-dose 5-day course (1 g TDS)	Branded: ₹150–300 (using 500 mg capsules × 2 per dose).
AOM — paediatric 10-day course (high-dose 80–90 mg/kg/day)	₹40–100 (1–2 bottles of suspension depending on child’s weight).
H. pylori eradication — 14-day triple therapy (amoxicillin component only)	Branded: ₹140–280 (28 capsules of 500 mg). H. pylori kit: ₹300–600 for the complete kit.
Single dose — endocarditis prophylaxis (2 g oral)	₹20–40 (4 capsules of 500 mg).

ℹ️ Amoxicillin is one of the most affordable antibiotics globally. Cost is almost never a barrier to treatment. Even the branded formulations are inexpensive by Indian standards. Government supply provides free or near-free amoxicillin through PHCs, CHCs, and district hospitals. Jan Aushadhi stores offer the lowest retail prices.

CLINICAL PEARLS

💡 1. Amoxicillin alone ≠ Amoxicillin-Clavulanate (Augmentin). Know when each is needed. The most common antimicrobial stewardship error in Indian outpatient practice is prescribing amoxicillin-clavulanate when amoxicillin alone would suffice. For uncomplicated GAS pharyngitis, non-severe pneumonia, uncomplicated sinusitis (initial therapy), and H. pylori eradication: amoxicillin alone is sufficient and preferred. Adding clavulanic acid unnecessarily: increases diarrhoea (~3× higher than amoxicillin alone), broadens spectrum (selecting for resistance), increases cost (2–3× more expensive), and provides NO additional benefit against the target pathogens. Reserve amoxicillin-clavulanate for: animal bites, chronic sinusitis, AOM treatment failure, aspiration pneumonia, diabetic foot infections, and suspected beta-lactamase-producing pathogen. [Evidence-based — antimicrobial stewardship guidelines; ICMR AMR guidance]

💡 2. For GAS pharyngitis in India: 500 mg BD × 10 days — the simplest effective regimen. This dosing provides the best combination of efficacy (equivalent GAS eradication to QID dosing), adherence (only 2 doses/day), and convenience (can be taken with meals). IAP 2017 Guidelines and WHO endorse this approach. The 10-day duration is NON-NEGOTIABLE for RF prevention. Do NOT accept shorter courses — even if the patient requests them. India carries the world’s highest RF/RHD burden — every incomplete course is a missed opportunity for RF prevention. [Evidence-based — IAP 2017 Guidelines; WHO; AHA]

💡 3. Myth vs Fact — “Amoxicillin reduces the effect of birth control pills.”
Myth: Widely believed by patients, pharmacists, and many prescribers in India — “If you take amoxicillin, your birth control pills won’t work.”
Fact: This has been definitively debunked. Large pharmacokinetic studies and population studies confirm that amoxicillin (and all penicillins) do NOT reduce combined oral contraceptive efficacy. The only antibiotic confirmed to reduce OCP efficacy is rifampicin (via potent CYP3A4 induction → increased oestrogen metabolism). The myth persists due to: (a) outdated teaching; (b) anecdotal reports of pregnancies occurring during antibiotic use (coincidence — contraceptive failure rate is ~1% per year regardless of antibiotics); © confusion with the rifampicin interaction. Actively debunk this at every opportunity — incorrect advice causes unnecessary anxiety, non-adherence to OCPs, and unintended pregnancies. [Evidence-based — FSRH UK Guideline 2019; large PK studies]

💡 4. EBV rash ≠ Penicillin allergy — protect your patients from a false allergy label. When a teenager or young adult with pharyngitis receives amoxicillin and develops a widespread maculopapular rash: consider mononucleosis (EBV) before labelling the patient as “penicillin-allergic.” ~70–100% of patients with EBV who receive aminopenicillins develop this rash — it is a virus-drug interaction, NOT an IgE-mediated allergy. If you label this patient as “penicillin-allergic,” they will be denied penicillin for life — including for syphilis treatment, RF prophylaxis, and endocarditis treatment. Document clearly: “Aminopenicillin rash in the setting of EBV — NOT penicillin allergy.” Consider checking monospot/EBV serology before prescribing amoxicillin in young adults with atypical pharyngitis. [Evidence-based — immunology and pharmacology of EBV-aminopenicillin interaction; clinical importance of accurate allergy documentation]

💡 5. Do NOT prescribe amoxicillin empirically for UTI in India — the resistance rate is >60%. Using amoxicillin empirically for a UTI in an Indian patient is expected to fail in the majority of cases. Empirical first-line for uncomplicated cystitis in India: nitrofurantoin 100 mg BD × 5 days (low resistance rates in India — ICMR AMR data show <15% E. coli resistance to nitrofurantoin). Amoxicillin for UTI should be used ONLY when culture confirms susceptibility — and in that context, it is an excellent narrow-spectrum choice. This is one of the most important antimicrobial stewardship messages for amoxicillin in Indian practice. [Evidence-based — ICMR AMR Surveillance Data; antimicrobial stewardship guidelines]

💡 6. Dispersible tablets (DT) — the ideal formulation for Indian public health. WHO-recommended amoxicillin dispersible tablets are stable at tropical room temperatures (no refrigeration needed), have no reconstitution shelf-life limitation, are individually dosed (no measuring errors), and are palatable when dispersed in water. They are increasingly available through NHM/government supply and Jan Aushadhi stores. For IMNCI/F-IMNCI community-based pneumonia treatment and for RF prevention programmes, DTs are the preferred formulation over dry syrups — especially in rural India where refrigeration is unreliable and measuring devices may not be available. Prescribers should preferentially prescribe DTs where available. [Evidence-based — WHO essential medicines recommendation; Practice-based — Indian public health programme experience]

VERSION

RxIndia v0.1 — 15 Mar 2026

REFERENCES

The following sources were used to compile this monograph. All text is originally written; no text was copied from any proprietary database.

CDSCO Product Insert — Mox (Amoxicillin) capsules 250 mg and 500 mg, Sun Pharma / Ranbaxy Laboratories. Approved indications, contraindications, dosing, and adverse effects. Also reviewed: Novamox (Cipla) product insert.
Indian Pharmacopoeia 2022 (IP 2022), Indian Pharmacopoeia Commission, Ghaziabad. 8th Edition. Monograph on Amoxicillin Trihydrate — specifications and official standards.
National List of Essential Medicines (NLEM) India 2022, Ministry of Health & Family Welfare, Government of India. Section 6.2 — Beta-lactam medicines: Amoxicillin capsules 250 mg/500 mg, oral suspension 125 mg/5 mL, dispersible tablets 250 mg are listed.
Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th Edition (2023). Chapter 58: Penicillins, Cephalosporins, and Other Beta-Lactam Antibiotics. Amoxicillin pharmacology, PK/PD, spectrum, clinical uses.
Harrison’s Principles of Internal Medicine, 21st Edition (2022). Chapters on: Pharyngitis; Pneumonia; Otitis Media; Sinusitis; Helicobacter pylori; UTI; Infective Endocarditis.
API Textbook of Medicine, 11th Edition (2019), Association of Physicians of India. Chapters on: Upper and Lower Respiratory Tract Infections; Pneumonia; Peptic Ulcer Disease and H. pylori; UTI; Rheumatic Fever.
IAP Guidelines on Acute Pharyngitis and RF Prevention (2017). Endorses amoxicillin 50 mg/kg/day BD × 10 days as first-line for GAS pharyngitis in children.
IAP Textbook of Pediatrics, 6th Edition (2021), Indian Academy of Pediatrics. Sections on: GAS pharyngitis, AOM, pneumonia, UTI, neonatal sepsis.
AAP/AAFP Clinical Practice Guideline: The Diagnosis and Management of Acute Otitis Media (2013). Lieberthal AS et al., Pediatrics 2013;131:e964–e999. High-dose amoxicillin (80–90 mg/kg/day) recommendation.
WHO Pocket Book of Hospital Care for Children (Indian Adaptation), MoHFW. Amoxicillin dosing for paediatric pneumonia.
MoHFW F-IMNCI Guidelines. WHO Simplified Antibiotic Regimen for PSBI in young infants (amoxicillin 50 mg/kg/dose oral BD + gentamicin IM).
WHO Recommendations on Newborn Health (2017). Community-based management of PSBI with simplified antibiotic regimens.
ICMR Treatment Guidelines for Antimicrobial Use in Common Syndromes. Referenced for empirical antibiotic guidance in Indian practice; AMR resistance data for E. coli, S. pneumoniae, and H. influenzae in India.
ICMR AMR Surveillance Data (Annual Reports). Referenced for E. coli amoxicillin resistance rates (>60–70%), pneumococcal penicillin resistance data, and H. pylori clarithromycin resistance data in India.
ISG (Indian Society of Gastroenterology) Guidelines on H. pylori Management. Referenced for triple therapy, quadruple therapy, and sequential therapy recommendations.
Maastricht VI / Florence Consensus Report on H. pylori Management (2022). Adapted for Indian practice — 14-day treatment duration, concomitant therapy.
BTS CAP Guidelines / NICE Pneumonia Guidelines (2019). Referenced for 5-day course evidence and amoxicillin as first-line for mild CAP.
BTS Bronchiectasis Guideline (2019) / ERS Bronchiectasis Guideline (2017). Referenced for bronchiectasis exacerbation treatment duration (14 days) and pathogen-specific guidance.
GOLD (Global Initiative for Chronic Obstructive Lung Disease) Report. Referenced for COPD exacerbation antibiotic criteria (Anthonisen classification).
IDSA Sinusitis Guidelines (2012). Referenced for ABRS antibiotic recommendations.
AHA IE Prevention Guidelines (2007, reaffirmed). Referenced for endocarditis prophylaxis — amoxicillin 2 g oral single dose.
FSRH UK Guideline on Drug Interactions with Hormonal Contraception (2019). Confirms no interaction between amoxicillin and combined OCPs. Referenced for OCP myth debunking.
NACO STI Treatment Guidelines. Referenced for chlamydia in pregnancy (amoxicillin as alternative).
PROPS Trial — Gaston et al., NEJM 1986. Referenced for SCD penicillin prophylaxis evidence (adapted for amoxicillin alternative use).
PATCH Trial — Thomas et al., NEJM 2013. Referenced for recurrent cellulitis prophylaxis (phenoxymethylpenicillin data — adapted context for amoxicillin comparisons).
NPPA (National Pharmaceutical Pricing Authority). DPCO ceiling prices for amoxicillin formulations.
PMBJP (Pradhan Mantri Bhartiya Janaushadhi Pariyojana). Product catalogue — amoxicillin listed.
CDSCO website (https://cdsco.gov.in). Reviewed for banned FDC notifications and NSQ alerts.
PvPI (Pharmacovigilance Programme of India). ADR reporting methodology.
Nelson Textbook of Pediatrics, 21st Edition (2020). Chapter on Otitis Media — high-dose amoxicillin PK/PD rationale.

Penicillins

Sub-classifications

Cumulative Drug Index

Quick Links